





## Strategies for improving health care seeking for maternal and newborn illnesses in low- and middle-income countries: a systematic review and meta-analysis

# Zohra S. Lassi<sup>1</sup>\*, Philippa F. Middleton<sup>1,2</sup>, Zulfiqar A. Bhutta<sup>3,4</sup> and Caroline Crowther<sup>1,5</sup>

<sup>1</sup>Australian Research Centre for Health of Women and Babies, Robinson Research Institute, School of Paediatrics and Reproductive Health, The University of Adelaide, Adelaide, Australia; <sup>2</sup>Women's and Children's Health Research Institute, The University of Adelaide, Adelaide, Australia; <sup>3</sup>Centre for Global Child Health, The Hospital for Sick Children, Toronto, Canada; <sup>4</sup>Centre of Excellence for Women and Child Health, The Aga Khan University, Karachi, Pakistan; <sup>5</sup>Liggins Institute, University of Auckland, Auckland, New Zealand

**Background**: Lack of appropriate health care seeking for ill mothers and neonates contributes to high mortality rates. A major challenge is the appropriate mix of strategies for creating demand as well as provision of services.

**Design:** Systematic review and meta-analysis of experimental studies (last search: Jan 2015) to assess the impact of different strategies to improve maternal and neonatal health care seeking in low- and middle-income countries (LMIC).

**Results**: Fifty-eight experimental [randomized controlled trials (RCTs), non-RCTs, and before-after studies] with 310,652 participants met the inclusion criteria. Meta-analyses from 29 RCTs with a range of different interventions (e.g. mobilization, home visitation) indicated significant improvement in health care seeking for neonatal illnesses when compared with standard/no care [risk ratio (RR) 1.40; 95 confidence interval (CI): 1.17–1.68, 9 studies, n = 30,572], whereas, no impact was seen on health care seeking for maternal illnesses (RR 1.06; 95% CI: 0.92–1.22, 5 studies, n = 15,828). These interventions had a significant impact on reducing stillbirths (RR 0.82; 95% CI: 0.73–0.93, 11 studies, n = 176,683), perinatal deaths (RR 0.84; 95% CI: 0.77–0.90, 15 studies, n = 279,618), and neonatal mortality (RR 0.80; 95% CI: 0.72–0.89, 20 studies, n = 248,848). On GRADE approach, evidence was high quality except for the outcome of maternal health care seeking, which was moderate.

*Conclusions*: Community-based interventions integrating strategies such as home visiting and counseling can help to reduce fetal and neonatal mortality in LMIC.

Keywords: health care seeking; maternal health; neonatal health; neonatal mortality; perinatal mortality; developing countries; low- and middle-income countries

\*Correspondence to: Zohra S. Lassi, Australian Research Centre for Health of Women and Babies, Robinson Research Institute, School of Paediatrics and Reproductive Health, The University of Adelaide, Adelaide, Australia, Email: zohra.lassi@adelaide.edu.au

To access the supplementary material for this article, please see Supplementary files under 'Article Tools'

Received: 23 February 2016; Revised: 10 April 2016; Accepted: 10 April 2016; Published: 10 May 2016

## Background

Globally, deaths of mothers and newborn babies are far too high. Every year an estimated 289,000 mothers and 2.62 million newborns die globally (1, 2). Complications during pregnancy and childbirth often lead to emergency situations, with a slim window of time to intervene. Maternal health complications contribute to 1.5 million early neonatal deaths and 1.4 million stillbirths, suggesting that there is a major gap requiring intervention around the time of birth and in the early postnatal period, a time when mothers and babies are most at risk (3). Worldwide, 50 million births take place at home without a skilled birth attendant (SBA) (4). Skilled attendance at birth remains unacceptably low in sub-Saharan Africa and Southern Asia and there are further wide disparities within countries, across socioeconomic status, geographic location, and educational status (5).

With 99% of maternal, newborn, and child deaths occurring in low- and middle-income countries (LMICs), increasing health resources and appropriate intervention in these countries is an urgent priority and global responsibility for reducing the burden of maternal and child mortality (6, 7). Antenatal care provides an opportunity to not only detect potential complications but also to prevent them. Birth preparedness - an easy to deliver and inexpensive intervention - can avert the brunt of maternal and perinatal mortalities. It includes different interventions such as identifying SBAs, the closest appropriate health facility, and sometimes funds for emergency transportation and consultation, all of which can reduce delays in obtaining care (8). During the last decade a number of systematic reviews have been published which have assessed interventions for improving maternal and newborn health (9-38). However, none of these have specifically focused on strategies to improve maternal and newborn health care seeking, the aim of this systematic review and meta-analysis.

## **Methods**

All experimental studies from LMICs that assessed the health care seeking behavior or pattern for maternal and newborn health care and illnesses were included. The population for this review included pregnant women at any gestation, postpartum women up to 6 weeks after giving birth, and neonates less than 28 days of life. We included studies that provided information and education for empowerment and change in the form of group meetings or individual one-to-one counseling at home or at primary health care facilities and compared them with standard/no care. The primary outcomes assessed were health care seeking for maternal and newborn illnesses. The secondary outcomes included maternal, neonatal, and perinatal mortality, stillbirths, (Panel 1) and maternal and newborn care outcomes, such as antenatal care, institutional births, and early initiation of breastfeeding.

Panel 1. Definitions.

- Neonatal death: death of a live born infant within 28 completed days of birth.
- Early neonatal death: deaths arising within 6 completed days of birth.
- Late neonatal death: deaths arising from 7 to 28 completed days of birth.
- \*Stillbirth: baby born with no signs of life at or after 28 weeks' gestation.
- \*Perinatal death: a stillbirth or early neonatal death.
- Maternal death: death of a woman while pregnant or within 42 days of cessation of pregnancy from any cause related to the pregnancy or its management, but not from accidental causes.

\*Stillbirths and perinatal deaths were defined differently in few studies. We considered author's definitions.

The protocol for this systematic review and meta-analysis was registered with PROSPERO 2012:CRD42012003 236 (www.metaxis.com/prospero/full\_doc.asp?RecordID= 3236). This review was conducted in accordance with methods of the Cochrane Collaboration (39). Ovid platform was used to search PubMed, MEDLINE, and EMBASE; Popline, the Cochrane Library, and Google Scholar were also searched up to 12 January2015. Search terms were a combination of and synonyms of ('care seeking' OR 'care-seeking' OR 'health care' OR 'health care seeking' OR 'community based intervention\*' OR 'community-based intervention\*') AND (mother\* OR maternal OR women OR newborn\* OR neonat\*) used as medical subject headings and keyword terms in the title/ abstract (Supplementary File 3). No language restrictions were applied. Grey literature (materials and research produced by organizations, [such as community health workers (CHWs) central, High Impact Practices etc.] outside of the traditional commercial or academic publishing and distribution channels) and reference lists of included studies were also searched to identify studies.

ZSL and PM independently reviewed the retrieved articles in two stages; first assessing relevance from the title and abstract, and if relevance was still unclear, reading the full text. Any disagreement was referred to a third reviewer (CC and ZAB). Studies were analyzed according to their study design i.e. randomized (and cluster) controlled trials (RCTs), non-randomized controlled trials (non-RCTs), and before-after studies.

ZSL and PM extracted data independently from each included study. Study design, country of study, participants, intervention, comparison, and duration of intervention were recorded for each study. If information was missing, authors were contacted. The methodological quality of studies was evaluated using standardized forms. The quality of controlled trials was assessed according to Cochrane methods (40). Prospective studies were graded using the methods described by the Effective Practice, Organization and Communication Cochrane review group (EPOC 2009) (41).

We performed statistical analysis of RCTs, non-RCTs, and before-after studies using the Review Manager software (42). For dichotomous data, we presented results as summary risk ratio (RR) and for continuous data we used mean difference (MD) with 95% confidence intervals (CIs). We included cluster-randomized trials in the analyses along with individually randomized trials and therefore their sample sizes were adjusted by the methods described in the Cochrane Handbook (43) using a design effect reported from the trial.

We have set out the mortality outcomes of the review in summary of findings tables prepared using the GRADE approach (44) using GRADE profiler software. For each of these outcomes, we assessed the quality of the evidence, considering within-study risk of bias (methodological quality), directness of evidence, heterogeneity, precision of effect estimates, and risk of publication bias. We have rated the quality of the body of evidence for each key outcome as 'high', 'moderate', 'low', or 'very low'.

The level of attrition was noted for each study. Heterogeneity between trials was assessed using the I-squared statistic, P value of  $< 0.1 (\chi^2)$ , and by visual inspection of forest plots. When high levels of heterogeneity between trials (I-squared exceeding 50%) were identified, further exploration was conducted by subgroup analysis and was tested by interaction tests. We applied random-effects meta-analysis as an overall summary when substantial methodological heterogeneity between and among the studies was found. A priori subgroup analyses were planned to identify the impact on health care seeking with different strategies (community mobilization, home visitation, combination of two, or perinatal health care/ education); and the extent of intervention (birth preparedness, birth preparedness, and recognition and referrals), or (birth preparedness, recognition and referrals and funds for emergency transportation). Potential publication bias was assessed using funnel plots (45).

## **Results**

Our initial search yielded 20,627 articles, 389 of which had relevant titles and abstracts. After reading the full text of these, 72 appeared to meet our inclusion criteria (Panel 2). After finding 14 of these 72 articles did not meet our inclusion criteria, we included and analyzed 58 original studies (90 published papers), of which 29 were RCTs, 15 were non-RCTs, and 14 were before-after studies (Fig. 1) (characteristics of included studies – Supplementary File 1).

A variety of different interventions and behaviors were assessed in the studies that met the eligibility criteria for inclusion (Panel 3). These interventions and behaviors included promoting routine antenatal care, institutional births, and early breastfeeding; provision of clean delivery kits; training of CHWs, SBA, and health care staff on birth preparedness; and provision of maternal and newborn health interventions. In several included studies these interventions were provided in the form of packages of different strategies including community mobilization, home visitation, or a combination of two.

## Primary outcomes: maternal and neonatal health care seeking

Meta-analyses of 27 RCTs (Table 1) with a range of different interventions (Panel 2) showed a 40% increase in health care seeking for neonatal illnesses when compared with standard/no care (RR 1.40; 95 CI: 1.17–1.68; 9 studies, n = 30,572). However, no significant impact was seen in improving health care seeking for maternal illnesses (RR 1.06; 95% CI: 0.92–1.22; 5 studies, n = 15,828). Heterogeneity was more than 85% for both these primary outcomes (Fig. 1a and b).

Subgroup analyses, based on intensity of interventions, suggested that birth preparedness alone as an intervention had no impact on improving health care seeking for maternal illnesses (RR 1.26; 95% CI: 0.57–2.80; 2 studies,



Panel 2. Search flow diagram.

Antenatal interventions	Intrapartum interventions	Postnatal interventions	Others
Promotion of routine antenatal care check-ups	<ul> <li>Provision of safe delivery kits</li> </ul>	Promotion of early and exclusive breastfeeding	TBA/CHW training
Tetanus toxoid immunization	<ul> <li>Clean delivery practices</li> </ul>	Kangaroo mother care/ thermoregulation	Advocacy group meeting
Nutritional counseling	Referrals for complications and emergencies	Newborn resuscitation	<ul> <li>Counseling and one-to-one session regarding birth preparedness and newborn care</li> </ul>
Iron/folate supplementation	, , , , , , , , , , , , , , , , , , ,	Case management of pneumonia	Training staff at health facility
Maternal health education		Recognition of neonatal danger signs	<ul> <li>Provision of drugs and supplies at health facilities</li> </ul>
Promotion of institutional deliveries		Referrals for sick     newborn	
Promotion of clean delivery kits		<ul> <li>Postnatal visitation</li> </ul>	
Promotion of breastfeeding			
Skin to skin care for newborns			
Care for umbilical cord			

n = 8,581) or newborn illnesses (RR 1.16; 95% CI: 0.85– 1.59; 5 studies, n = 25,857). Similarly, recognition and referrals for maternal complications showed no impact on improving health care seeking for maternal illnesses (RR 0.96; 95% CI: 0.83–1.12; 1 study, n = 876). When birth preparedness counseling was combined with recog-

nition of illnesses and provision of referrals by CHWs, health care seeking improved for both maternal illnesses (RR 1.15; 95% CI: 1.11–1.20; 1 study, n = 3,810) and newborn illnesses (RR 1.65; 95% CI: 1.46–1.86; 4 studies, n = 4,715). However, when birth preparedness was combined with recognition and referrals along with collecting

Table 1. Results from randomized controlled trials

		Number of studies	
Outcomes	Summary estimates	and participants	Heterogeneity
Primary outcomes			
Health care seeking for maternal illnesses	RR 1.06; 95% CI: 0.92, 1.22	5 (n = 15,828)	$\tau^2$ 0.03; $\chi^2 P < 0.00001$ ; $I^2$ 93%
Health care seeking for neonatal illnesses	RR 1.40; 95% CI: 1.17, 1.68	9 ( <i>n</i> = 31,006)	$\tau^2$ 0.07; $\chi^2 P < 0.00001$ ; $I^2$ 87%
Secondary outcomes			
Mortality outcomes			
Maternal mortality	RR 0.80; 95% CI: 0.65, 1.00	8 ( <i>n</i> = 114,196)	τ <sup>2</sup> 0.03; χ <sup>2</sup> <i>P</i> =0.07; <i>I</i> <sup>2</sup> 30%
Neonatal mortality	RR 0.80; 95% CI: 0.72, 0.89	21 (n = 248,848)	$\tau^2$ 0.06; $\chi^2 P < 0.00001$ ; $I^2$ 83%
Early neonatal mortality	RR 0.70; 95% CI: 0.61, 0.81	11 ( <i>n</i> = 113,147)	$\tau^2$ 0.05; $\chi^2 P < 0.00001$ ; $I^2$ 77%
Late neonatal mortality	RR 0.77; 95% CI: 0.64, 0.93	9 ( <i>n</i> = 108,359)	τ <sup>2</sup> 0.03; χ <sup>2</sup> <i>P</i> =0.08; <i>I</i> <sup>2</sup> 42%
Stillbirths	RR 0.82; 95% CI: 0.74, 0.92	12 ( <i>n</i> = 176,683)	$\tau^2$ 0.03; $\chi^2$ <i>P</i> =0.0002; <i>I</i> <sup>2</sup> 68%
Perinatal mortality	RR 0.84; 95% CI: 0.78, 0.90	16 ( <i>n</i> = 279,618)	$\tau^2$ 0.02; $\chi^2 P < 0.00001$ ; $I^2$ 68%
Morbidity outcomes			
Any perceived maternal illnesses	RR 0.87; 95% CI: 0.65, 1.15	3 (n = 26,005)	τ <sup>2</sup> 0.00; χ <sup>2</sup> <i>P</i> =0.55; <i>I</i> <sup>2</sup> 0%
Any perceived neonatal illnesses	RR 0.61; 95% CI: 0.43, 0.85	2 (n = 12,019)	τ <sup>2</sup> 0.00; χ <sup>2</sup> <i>P</i> =0.79; <i>I</i> <sup>2</sup> 0%
Process outcomes			
Any antenatal care	RR 1.26; 95% CI: 1.16, 1.37	13 ( <i>n</i> = 141,006)	$\tau^2$ 0.02; $\chi^2 P < 0.00001$ ; $I^2$ 96%
Any tetanus toxoid immunization	RR 1.07; 95% CI: 1.04, 1.11	8 (n = 83,243)	$\tau^2$ 0.00; $\chi^2 P < 0.00001$ ; $I^2$ 81%
Iron/folate supplementation	RR 1.49; 95% CI: 1.06, 2.11	6 (n = 81,706)	$\tau^2$ 0.23; $\chi^2 P < 0.00001$ ; $I^2$ 99%
Birthing by skilled birth attendant	RR 1.15; 95% CI: 0.99, 1.34	7 (n = 53,583)	$\tau^2$ 0.04; $\chi^2 P < 0.00001$ ; $I^2$ 89%
Institutional births	RR 1.15; 95% CI: 1.05, 1.26	16 ( <i>n</i> = 116,848)	$\tau^2$ 0.03; $\chi^2$ <i>P</i> < 0.00001; <i>I</i> <sup>2</sup> 84%
Initiation of breastfeeding within an hour of birth	RR 1.77; 95% CI: 1.43, 2.19	14 ( <i>n</i> = 100,272)	$\tau^2$ 0.16; $\chi^2 P < 0.00001$ ; $l^2$ 98%

Significant estimates are provided in BOLD.

## 1.1 Health care seeking for maternal illnesses

Chudu an Cubanaun	le efficie le Detiel	In	tervention (	Control	Mainhé	Risk Ratio	Risk Ratio
Study or Subgroup	log[RISK Ratio]	SE	Total	Total	weight	IV, Random, 95% CI	IV, Random, 95% CI
1.1.1 Community mo	Dilization	0.0054		0504	10.00		
Manandhar 2004	0.575	0.0851	3190	3524	12.9%	1.78 [1.50, 2.10]	
Midhet 2010 (1)	-0.2135	0.0432	836	511	14.9%	0.81 [0.74, 0.88]	
Tripothy 2010 (2)	-0.0524	0.0409	703	000	15.0%	0.95 [0.88, 1.03]	
Subtotal (95% CI)	-0.2465	0.5557	5674	5468	46.1%	1.05 [0.39, 1.50]	-
Heterogeneity: Tau <sup>2</sup> -	0.09° Chiž – 69.5	7 df = 3 (P	< 0.00001) F	- 96%		100 [0111, 1110]	T
Test for overall effect:	7 = 0.32 (P = 0.74	7, ar = 5 (r 5)	- 0.00001),1	- 30 %			
reaction over all encore	2 = 0.02 (r = 0.10	~					
1.1.2 Home visitation	i i i i i i i i i i i i i i i i i i i						
Bashour 2008 (3)	0.0075	0.1075	294	148	11.6%	1.01 [0.82, 1.24]	
Bashour 2008 (4)	-0.0855	0.1121	285	149	11.4%	0.92 [0.74, 1.14]	
Subtotal (95% CI)			579	297	23.0%	0.96 [0.83, 1.12]	<b>*</b>
Heterogeneity: Tau <sup>2</sup> =	0.00; Chi <sup>2</sup> = 0.36	df = 1 (P =	0.55); I <sup>2</sup> = 09	6			
Test for overall effect:	Z = 0.48 (P = 0.63	3)					
1.1.3 Community mo	bilization + nome	visitation					
Kumar 2008 (5)	0.1394	0.029	1122	564	15.4%	1.15 [1.09, 1.22]	•
Kumar 2008 (6) Subtotal (95% CI)	0.1459	0.0273	1559	1120	15.5%	1.16[1.10, 1.22]	Ī
Hotorogonoity Tou?-	0.00.068-0.02	df - 1 /P -	0.07\.12-00	4	30.5%	1.15 [1.11, 1.20]	'
Test for overall effect:	7 - 7 19 (P < 0.00	0001)	0.07),1 = 05	0			
resciol overall ellect.	2 - 7.13 (F < 0.00	,001)					
Total (95% CI)			8934	6894	100.0%	1.06 [0.92, 1.22]	•
Heterogeneity: Tau <sup>2</sup> =	0.03: Chi <sup>2</sup> = 103.	75. $df = 7.0$	< 0.00001).	F = 93%			
Test for overall effect:	Z = 0.86 (P = 0.39	3)					0.1 0.2 0.5 1 2 5 10
Test for subgroup diff	ferences: Chi <sup>2</sup> = 5	.29, df = 2 (	P = 0.07), I <sup>2</sup> =	62.2%			Favours control Favours Intervention
Footnotes							
(1) Women - Informat	tion and Education	n for Empo	werment and	Change			
(2) Couple - Informati	on and Education	for Empoy	verment and	Change			
(3) Single visit							
(4) Four visits							
(5) Essential Newbor	n Care + thermo s	spot					
(6) Essentail Newbor	n Care						
1.2 Health	care seekin	g tor ne	eonatal I	liness	es		
		0					
		In	tervention (	Control		Risk Ratio	Risk Ratio
Study or Subgroup	log[Risk Ratio]	In SE	tervention ( Total	Control Total	Weight	Risk Ratio IV, Random, 95% Cl	Risk Ratio IV, Random, 95% Cl
Study or Subgroup 1.2.1 Community mo	log[Risk Ratio] bilization	In SE	tervention ( Total	Control Total	Weight	Risk Ratio IV, Random, 95% CI	Risk Ratio IV, Random, 95% Cl
Study or Subgroup 1.2.1 Community mo Azad 2010	log[Risk Ratio] bilization -0.1165	0.1153	tervention ( Total 4457	Control Total 4441	Weight	Risk Ratio IV, Random, 95% CI 0.89 [0.71, 1.12]	Risk Ratio IV, Random, 95% Cl
Study or Subgroup 1.2.1 Community mo Azad 2010 Manandhar 2004	log[Risk Ratio] bilization -0.1165 0.6097	0.1153 0.1073	tervention ( Total 4457 2823	Control Total 4441 3107	Weight 10.2% 10.4%	Risk Ratio IV, Random, 95% CI 0.89 [0.71, 1.12] 1.84 [1.49, 2.27]	Risk Ratio IV, Random, 95% Cl
Study or Subgroup 1.2.1 Community mo Azad 2010 Manandhar 2004 More 2012	log[Risk Ratio] bilization -0.1165 0.6097 -0.0834	0.1153 0.1073 0.118	4457 2823 2590	20000000000000000000000000000000000000	Weight 10.2% 10.4% 10.1%	Risk Ratio IV, Random, 95% CI 0.89 [0.71, 1.12] 1.84 [1.49, 2.27] 0.92 [0.73, 1.16]	Risk Ratio IV, Random, 95% Cl
Study or Subgroup 1.2.1 Community mo Azad 2010 Manandhar 2004 More 2012 Tripathy 2010	log[Risk Ratio] bilization -0.1165 0.6097 -0.0834 0.4253	0.1153 0.1073 0.118 0.3503	tervention ( Total 4457 2823 2590 940	<b>Control</b> <b>Total</b> 4441 3107 2566 1050	Weight 10.2% 10.4% 10.1% 4.4%	Risk Ratio IV, Random, 95% CI 0.89 [0.71, 1.12] 1.84 [1.49, 2.27] 0.92 [0.73, 1.16] 1.53 [0.77, 3.04]	Risk Ratio IV, Random, 95% Cl
Study or Subgroup 1.2.1 Community mo Azad 2010 Manandhar 2004 More 2012 Tripathy 2010 Subtotal (95% CI)	log[Risk Ratio] bilization -0.1165 0.6097 -0.0834 0.4253	0.1153 0.1073 0.118 0.3503	tervention ( Total 4457 2823 2590 940 10810	4441 3107 2566 1050 <b>11164</b>	Weight 10.2% 10.4% 10.1% 4.4% 35.1%	Risk Ratio IV, Random, 95% Cl 0.89 [0.71, 1.12] 1.84 [1.49, 2.27] 0.92 [0.73, 1.16] 1.53 [0.77, 3.04] 1.20 [0.79, 1.83]	Risk Ratio IV, Random, 95% Cl
Study or Subgroup 1.2.1 Community mo Azad 2010 Manandhar 2004 More 2012 Tripathy 2010 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> =	log[Risk Ratio] bilization -0.1165 0.6097 -0.0834 0.4253 : 0.15; Chi <sup>2</sup> = 28.1	0.1153 0.1073 0.1073 0.118 0.3503 1, df = 3 (P	tervention ( Total 4457 2823 2590 940 10810 < 0.00001); F	Control Total 4441 3107 2566 1050 11164 2 = 89%	Weight 10.2% 10.4% 10.1% 4.4% 35.1%	Risk Ratio IV, Random, 95% CI 0.89 [0.71, 1.12] 1.84 [1.49, 2.27] 0.92 [0.73, 1.16] 1.53 [0.77, 3.04] 1.20 [0.79, 1.83]	Risk Ratio IV, Random, 95% Cl
Study or Subgroup 1.2.1 Community mo Azad 2010 Manandhar 2004 More 2012 Tripathy 2010 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect:	log[Risk Ratio] bilization -0.1165 0.6097 -0.0834 0.4253 : 0.15; Chi <sup>2</sup> = 28.1 Z = 0.87 (P = 0.38	0.1153 0.1073 0.1073 0.118 0.3503 1, df = 3 (P	tervention ( Total 4457 2823 2590 940 10810 < 0.00001); F	4441           3107           2566           1050           11164           * = 89%	Weight 10.2% 10.4% 10.1% 4.4% 35.1%	Risk Ratio IV, Random, 95% CI 0.89 [0.71, 1.12] 1.84 [1.49, 2.27] 0.92 [0.73, 1.16] 1.53 [0.77, 3.04] 1.20 [0.79, 1.83]	Risk Ratio IV, Random, 95% Cl
Study or Subgroup 1.2.1 Community mo Azad 2010 Manandhar 2004 More 2012 Tripathy 2010 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect:	log[Risk Ratio] bilization -0.1165 0.6097 -0.0834 0.4253 0.16; Chi <sup>z</sup> = 28.1 Z = 0.87 (P = 0.38	0.1153 0.1073 0.1073 0.118 0.3503 1, df = 3 (P	tervention ( <u>Total</u> 4457 2823 2590 940 10810 < 0.00001); F	Control Total 4441 3107 2566 1050 11164 *= 89%	Weight 10.2% 10.4% 10.1% 4.4% 35.1%	Risk Ratio IV, Random, 95% CI 0.89 [0.71, 1.12] 1.84 [1.49, 2.27] 0.92 [0.73, 1.16] 1.53 [0.77, 3.04] 1.20 [0.79, 1.83]	Risk Ratio IV, Random, 95% Cl
Study or Subgroup 1.2.1 Community mo Azad 2010 Manandhar 2004 More 2012 Tripathy 2010 Subtotal (95% Cl) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 1.2.2 Home visitation	log[Risk Ratio] bilization -0.1165 0.6097 -0.0834 0.4253 : 0.15; Chi <sup>2</sup> = 28.1 Z = 0.87 (P = 0.38	0.1153 0.1073 0.1073 0.118 0.3503 1, df = 3 (P	tervention ( Total 4457 2823 2590 940 10810 < 0.00001); F	Control Total 4441 3107 2566 1050 11164 <sup>2</sup> = 89%	Weight 10.2% 10.4% 10.1% 4.4% 35.1%	Risk Ratio IV, Random, 95% CI 0.89 [0.71, 1.12] 1.84 [1.49, 2.27] 0.92 [0.73, 1.16] 1.53 [0.77, 3.04] 1.20 [0.79, 1.83]	Risk Ratio IV, Random, 95% Cl
Study or Subgroup 1.2.1 Community mo Azad 2010 Manandhar 2004 More 2012 Tripathy 2010 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 1.2.2 Home visitation Bari 2006	log[Risk Ratio] bilization -0.1165 0.6097 -0.0834 0.4253 ≎ 0.15; Chi <sup>2</sup> = 28.1 Z = 0.87 (P = 0.38 0.5785	0.1153 0.1073 0.1073 0.118 0.3503 1, df = 3 (P 3) 0.1002	tervention ( Total 4457 2823 2590 940 10810 < 0.00001); F 270	Control Total 4441 3107 2566 1050 11164 *= 89%	Weight 10.2% 10.4% 10.1% 4.4% 35.1%	Risk Ratio IV, Random, 95% CI 0.89 [0.71, 1.12] 1.84 [1.49, 2.27] 0.92 [0.73, 1.16] 1.53 [0.77, 3.04] 1.20 [0.79, 1.83] 1.78 [1.47, 2.17]	Risk Ratio IV, Random, 95% Cl
Study or Subgroup 1.2.1 Community mo Azad 2010 Manandhar 2004 More 2012 Tripathy 2010 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 1.2.2 Home visitation Bari 2006 Darmstadt 2010	log[Risk Ratio]           bilization           -0.1165           0.6097           -0.0834           0.4253           0.15; Chi <sup>2</sup> = 28.1           Z = 0.87 (P = 0.38)           0.5785           0.4804	0.1153 0.1073 0.1073 0.118 0.3503 1, df = 3 (P 3) 0.1002 0.0835	tervention ( Total 4457 2823 2590 940 10810 < 0.00001); F 270 355	Control Total 4441 3107 2566 1050 11164 *= 89% 257 400	Weight 10.2% 10.4% 10.1% 4.4% 35.1%	Risk Ratio IV, Random, 95% CI 0.89 [0.71, 1.12] 1.84 [1.49, 2.27] 0.92 [0.73, 1.16] 1.53 [0.77, 3.04] 1.20 [0.79, 1.83] 1.20 [0.79, 1.83]	Risk Ratio IV, Random, 95% Cl
Study or Subgroup 1.2.1 Community mo Azad 2010 Manandhar 2004 More 2012 Tripathy 2010 Subtotal (95% CI) Heterogeneity. Tau <sup>2</sup> = Test for overall effect: 1.2.2 Home visitation Bari 2006 Darmstadt 2010 Kirkwood 2013	log[Risk Ratio] bilization -0.1185 0.6097 -0.0834 0.4253 0.15; Chi <sup>2</sup> = 28.1 Z = 0.87 (P = 0.38 0.5785 0.4804 0.3577	0.1153 0.1073 0.118 0.3503 1, df = 3 (P 3) 0.1002 0.0835 0.1024	tervention ( Total 4457 2823 2590 940 10810 < 0.00001); F 270 355 102	Control Total 4441 3107 2566 1050 11164 *= 89% 257 400 77	Weight 10.2% 10.4% 10.1% 4.4% 35.1%	Risk Ratio IV, Random, 95% CI 0.89 [0.71, 1.12] 1.84 [1.49, 2.27] 0.92 [0.73, 1.16] 1.53 [0.77, 3.04] 1.20 [0.79, 1.83] 1.78 [1.47, 2.17] 1.62 [1.37, 1.90] 1.43 [1.17, 1.75]	Risk Ratio IV, Random, 95% CI
Study or Subgroup 1.2.1 Community mo Azad 2010 Manandhar 2004 More 2012 Tripathy 2010 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 1.2.2 Home visitation Bari 2006 Darmstadt 2010 Kirkwood 2013 Subtotal (95% CI)	log[Risk Ratio]           bilization         -0.1165           0.6097         -0.0834           0.4253         0.4253 $: 0.15; Chi^2 = 28.1$ Z = 0.87 (P = 0.38)           0         0.5785         0.4804           0.3577         0.3577	In SE 0.1153 0.1073 0.118 0.3503 1, df = 3 (P 0.1002 0.0835 0.1024	tervention ( Total 4457 2823 2590 940 10810 < 0.00001); F 270 355 102 727	20000000000000000000000000000000000000	Weight 10.2% 10.4% 10.1% 4.4% 35.1% 10.6% 11.1% 10.6% 32.3%	Risk Ratio IV, Random, 95% CI 0.89 [0.71, 1.12] 1.84 [1.49, 2.27] 0.92 [0.73, 1.16] 1.53 [0.77, 3.04] 1.20 [0.79, 1.83] 1.20 [0.79, 1.83] 1.78 [1.47, 2.17] 1.62 [1.37, 1.90] 1.43 [1.17, 1.75] 1.61 [1.43, 1.81]	Risk Ratio IV, Random, 95% Cl
Study or Subgroup 1.2.1 Community mo Azad 2010 Manandhar 2004 More 2012 Tripathy 2010 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 1.2.2 Home visitation Bari 2006 Darmstadt 2010 Kirkwood 2013 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> =	log[Risk Ratio]           bilization           -0.1165           0.6097           -0.0834           0.4253           0.15; Chi <sup>2</sup> = 28.1           Z = 0.87 (P = 0.38)           0.5785           0.4804           0.3577           0.03677	In SE 0.1153 0.1073 0.118 0.3503 1, df = 3 (P 3) 0.1002 0.0835 0.1024 , df = 2 (P =	tervention ( Total 4457 2823 2590 940 10810 < 0.00001); F 270 355 102 727 5.030; F = 16	20000000000000000000000000000000000000	Weight 10.2% 10.4% 10.1% 4.4% 35.1% 10.6% 11.1% 10.6% 32.3%	Risk Ratio IV, Random, 95% CI 0.89 [0.71, 1.12] 1.84 [1.49, 2.27] 0.92 [0.73, 1.16] 1.53 [0.77, 3.04] 1.20 [0.79, 1.83] 1.20 [0.79, 1.83] 1.78 [1.47, 2.17] 1.62 [1.37, 1.90] 1.43 [1.17, 1.75] 1.61 [1.43, 1.81]	Risk Ratio IV, Random, 95% Cl
Study or Subgroup 1.2.1 Community mo Azad 2010 Manandhar 2004 More 2012 Tripathy 2010 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 1.2.2 Home visitation Bari 2006 Darmstadt 2010 Kirkwood 2013 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect:	log[Risk Ratio] bilization -0.1165 0.6097 -0.0834 0.4253 0.4253 0.4253 0.4253 0.4253 0.4253 0.4804 0.5775 0.4804 0.3577 0.4804 0.3577 0.4804 0.3577 0.4804 0.3577 0.4804 0.3577 0.4804 0.3577 0.48040000000000	In SE 0.1153 0.1073 0.118 0.3503 1, df = 3 (P 3) 0.1002 0.0835 0.024 , df = 2 (P = 3001)	tervention 0 Total 4457 2823 2590 940 10810 < 0.00001); F 270 355 102 727 : 0.30); P = 16	2000 Total 4441 3107 2566 1050 11164 *= 89% 257 400 77 734	Weight 10.2% 10.4% 10.1% 4.4% 35.1% 10.6% 11.1% 10.6% 32.3%	Risk Ratio IV, Random, 95% CI 0.89 [0.71, 1.12] 1.84 [1.49, 2.27] 0.92 [0.73, 1.16] 1.53 [0.77, 3.04] 1.20 [0.79, 1.83] 1.20 [0.79, 1.83] 1.78 [1.47, 2.17] 1.62 [1.37, 1.90] 1.43 [1.71, 1.75] 1.61 [1.43, 1.81]	Risk Ratio IV, Random, 95% Cl
Study or Subgroup 1.2.1 Community mo Azad 2010 Manandhar 2004 More 2012 Tripathy 2010 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 1.2.2 Home visitation Bari 2006 Darmstadt 2010 Kirkwood 2013 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect:	log[Risk Ratio]           bilization         -0.1165           0.6097         -0.0834           0.4253         0.4253 $: 0.15; Chi^2 = 28.1$ Z = 0.87 (P = 0.38)           0.5785         0.4804           0.3577         : $: 0.00; Chi^2 = 2.38$ Z = 7.96 (P < 0.00)	In SE 0.1153 0.1073 0.118 0.3503 1, df = 3 (P 3) 0.1002 0.0835 0.1002 0.0835 0.1024 df = 2 (P = 0001)	tervention 0 Total 4457 2823 2590 940 10810 < 0.00001); F 270 365 102 270 365 102 270 365 102 270 365 102 102 103 103 103 103 103 103 103 103	Control Total 4441 3107 2566 1050 11164 <sup>2</sup> = 89% 257 400 77 734	Weight 10.2% 10.4% 10.1% 4.4% 35.1% 10.6% 11.1% 10.6% 32.3%	Risk Ratio IV, Random, 95% CI 0.89 [0.71, 1.12] 1.84 [1.49, 2.27] 0.92 [0.73, 1.16] 1.53 [0.77, 3.04] 1.20 [0.79, 1.83] 1.20 [0.79, 1.83] 1.78 [1.47, 2.17] 1.62 [1.37, 1.90] 1.43 [1.17, 1.75] 1.61 [1.43, 1.81]	Risk Ratio IV, Random, 95% Cl
Study or Subgroup 1.2.1 Community mo Azad 2010 Manandhar 2004 More 2012 Tripathy 2010 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 1.2.2 Home visitation Bari 2006 Darmstadt 2010 Kirkwood 2013 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 1.2.3 Community mo	log[Risk Ratio]           bilization           -0.1165           0.6097           -0.0834           0.4253           0.15; Chi <sup>#</sup> = 28.1           Z = 0.87 (P = 0.36)           0.5785           0.4804           0.3577           0.00; Chi <sup>#</sup> = 2.38           Z = 7.96 (P < 0.00)	In SE 0.1153 0.1073 0.118 0.3503 1, df = 3 (P 3) 0.1002 0.0835 0.1024 , df = 2 (P = 0001) visitation	tervention ( Total 4457 2823 2590 940 10810 < 0.00001); F 270 355 102 727 ; 0.30); F = 16	2000 Total 4441 3107 2566 1050 11164 <sup>2</sup> = 89% 257 400 77 734 <sup>5</sup> %	Weight 10.2% 10.4% 10.1% 4.4% 35.1% 10.6% 11.1% 10.6% 32.3%	Risk Ratio IV, Random, 95% CI 0.89 [0.71, 1.12] 1.84 [1.49, 2.27] 0.92 [0.73, 1.16] 1.53 [0.77, 3.04] 1.20 [0.79, 1.83] 1.20 [0.79, 1.83] 1.78 [1.47, 2.17] 1.62 [1.37, 1.90] 1.43 [1.17, 1.75] 1.61 [1.43, 1.81]	Risk Ratio IV, Random, 95% Cl
Study or Subgroup 1.2.1 Community mo Azad 2010 Manandhar 2004 More 2012 Tripathy 2010 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 1.2.2 Home visitation Bari 2006 Darmstadt 2010 Kirkwood 2013 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 1.2.3 Community mo Kumar 2008 (1)	log[Risk Ratio]           bilization         -0.1165           0.6097         -0.0834           0.4253         0.4253           c0.15; Chi <sup>2</sup> = 28.1         Z = 0.87 (P = 0.36           0.5785         0.4804           0.3677         50.4804           2 = 7.96 (P < 0.00	In SE 0.1153 0.1073 0.118 0.3503 1, df = 3 (P 3) 0.1002 0.0835 0.1002 0.0835 0.1002 0.01024 eff = 2 (P = 10001) visitation 0.0816	tervention ( Total 4457 2823 2590 940 10810 < 0.00001); F 270 355 102 727 : 0.30); IP = 16 1522	Control Total 4441 3107 2566 1050 11164 *= 89% 257 400 77 734 *%	Weight 10.2% 10.4% 10.1% 4.4% 35.1% 10.6% 11.1% 10.6% 32.3%	Risk Ratio IV, Random, 95% CI 0.89 [0.71, 1.12] 1.84 [1.49, 2.27] 0.92 [0.73, 1.16] 1.53 [0.77, 3.04] 1.20 [0.79, 1.83] 1.78 [1.47, 2.17] 1.62 [1.37, 1.90] 1.43 [1.7, 1.75] 1.61 [1.43, 1.81]	Risk Ratio IV, Random, 95% Cl
Study or Subgroup 1.2.1 Community mo Azad 2010 Manandhar 2004 More 2012 Tripathy 2010 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 1.2.2 Home visitation Bari 2006 Darmstadt 2010 Kirkwood 2013 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 1.2.3 Community mo Kumar 2008 (1) Kumar 2008 (2)	log[Risk Ratio]           bilization         -0.1165           0.6097         -0.0834           0.4253         0.4253           : 0.15; Chi <sup>#</sup> = 28.1         Z           .0.57; Chi <sup>#</sup> = 0.38         0.4804           0.3577         0.4804           0.3577         0.00; Chi <sup>#</sup> = 2.38           Z = 7.96 (P < 0.00	In SE 0.1153 0.1073 0.118 0.3503 1, df = 3 (P 3) 0.1002 0.0835 0.1024 0.0835 0.1024 df = 2 (P = 1001) visitation 0.0803	tervention 0 Total 4457 2823 2590 940 10810 < 0.00001); F 270 365 102 727 : 0.30); F = 16 1522 1087	Control Total 4441 3107 2566 1050 11164 *= 89% 257 400 77 734 %	Weight 10.2% 10.4% 10.1% 4.4% 35.1% 10.6% 11.1% 11.1% 11.1%	Risk Ratio IV, Random, 95% CI 0.89 [0.71, 1.12] 1.84 [1.49, 2.27] 0.92 [0.73, 1.16] 1.53 [0.77, 3.04] 1.20 [0.79, 1.83] 1.78 [1.47, 2.17] 1.62 [1.37, 1.90] 1.43 [1.17, 1.75] 1.61 [1.43, 1.81] 1.47 [1.25, 1.72] 1.99 [1.70, 2.32]	Risk Ratio IV, Random, 95% Cl
Study or Subgroup 1.2.1 Community mo Azad 2010 Manandhar 2004 More 2012 Tripathy 2010 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 1.2.2 Home visitation Bari 2006 Darmstadt 2010 Kirkwood 2013 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 1.2.3 Community mo Kumar 2008 (1) Kumar 2008 (2) Subtotal (95% CI)	log[Risk Ratio]           bilization           -0.1165           0.6097           -0.0834           0.4253           0.15; Chi <sup>#</sup> = 28.1           Z = 0.87 (P = 0.36           0.5785           0.4804           0.3577           0.00; Chi <sup>#</sup> = 2.38           Z = 7.96 (P < 0.00	In SE 0.1153 0.1073 0.118 0.3503 1, df = 3 (P 3) 0.1002 0.0835 0.1024 , df = 2 (P = 0001) visitation 0.0816 0.0803	tervention ( Total 4457 2823 2590 940 10810 < 0.00001); F 270 355 102 727 727 0.30); F = 16 1522 1087 2609	Control Total 4441 3107 2566 1050 11164 *= 89% 257 400 77 734 %	Weight 10.2% 10.4% 10.1% 4.4% 35.1% 10.6% 11.1% 32.3% 11.1% 22.2%	Risk Ratio IV, Random, 95% CI 0.89 [0.71, 1.12] 1.84 [1.49, 2.27] 0.92 [0.73, 1.16] 1.53 [0.77, 3.04] 1.20 [0.79, 1.83] 1.78 [1.47, 2.17] 1.62 [1.37, 1.90] 1.43 [1.17, 1.75] 1.61 [1.43, 1.81] 1.47 [1.25, 1.72] 1.99 [1.70, 2.32] 1.71 [1.27, 2.29]	Risk Ratio IV, Random, 95% Cl
Study or Subgroup 1.2.1 Community mo Azad 2010 Manandhar 2004 More 2012 Tripathy 2010 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 1.2.2 Home visitation Bari 2006 Darmstadt 2010 Kirkwood 2013 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 1.2.3 Community mo Kumar 2008 (1) Kumar 2008 (2) Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> =	log[Risk Ratio]           bilization         -0.1165           0.6097         -0.0834           0.4253         0.4253           : 0.15; Chi <sup>2</sup> = 28.1         Z = 0.87 (P = 0.38           0.5785         0.4804           0.3577         : 0.3677           : 0.00; Chi <sup>2</sup> = 2.38         Z = 7.96 (P < 0.02	In SE 0.1153 0.1073 0.118 0.3503 1, df = 3 (P 3) 0.1002 0.0835 0.1024 0.0816 0.0816 0.0816 0.0816 0.0803 , df = 1 (P =	tervention 0 Total 4457 2823 2590 940 10810 < 0.00001); F 270 355 102 727 0.30); F= 16 1522 1087 2609 0.009); F= 8	Control Total 4441 3107 2566 1050 11164 *= 89% 257 400 77 734 % 539 540 1079	Weight 10.2% 10.4% 10.1% 4.4% 35.1% 10.6% 11.1% 10.6% 32.3% 11.1% 11.1% 22.2%	Risk Ratio IV, Random, 95% CI 0.89 [0.71, 1.12] 1.84 [1.49, 2.27] 0.92 [0.73, 1.16] 1.53 [0.77, 3.04] 1.20 [0.79, 1.83] 1.78 [1.47, 2.17] 1.62 [1.37, 1.90] 1.43 [1.71, 1.75] 1.61 [1.43, 1.81] 1.47 [1.25, 1.72] 1.99 [1.70, 2.32] 1.71 [1.27, 2.29]	Risk Ratio IV, Random, 95% Cl
Study or Subgroup 1.2.1 Community mo Azad 2010 Manandhar 2004 More 2012 Tripathy 2010 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 1.2.2 Home visitation Bari 2006 Darmstadt 2010 Kirkwood 2013 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 1.2.3 Community mo Kumar 2008 (2) Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: Heterogeneity: Tau <sup>2</sup> = Test for overall effect: Heterogeneity: Tau <sup>2</sup> =	log[Risk Ratio]           bilization         -0.1165           0.6097         -0.0834           0.4253         0.4253           : 0.15; Chi <sup>#</sup> = 28.1         Z           Z = 0.87 (P = 0.38         0.4044           0.3577         0.4044           0.3577         0.4004           0.3577         0.00; Chi <sup>#</sup> = 2.38           Z = 7.96 (P < 0.00	In SE 0.1153 0.1073 0.118 0.3503 1, df = 3 (P 0.1002 0.0835 0.1024 0.0835 0.1024 0.0835 0.1024 0.0835 0.1024 0.0835 0.1024 0.0835 0.001 Visitation 0.0803 0.0803 0.0803 0.0803	tervention ( Total 4457 2823 2590 940 10810 < 0.00001); F 270 365 102 727 : 0.30); F = 18 1522 1087 2609 : 0.0009; F = 8	Control Total 4441 3107 2566 1050 11164 *= 89% 257 400 77 734 % 539 540 1079	Weight 10.2% 10.4% 10.1% 4.4% 35.1% 10.6% 11.1% 32.3%	Risk Ratio IV, Random, 95% CI 0.89 [0.71, 1.12] 1.84 [1.49, 2.27] 0.92 [0.73, 1.16] 1.53 [0.77, 3.04] 1.20 [0.79, 1.83] 1.78 [1.47, 2.17] 1.62 [1.37, 1.90] 1.43 [1.17, 1.75] 1.61 [1.43, 1.81] 1.47 [1.25, 1.72] 1.99 [1.70, 2.32] 1.71 [1.27, 2.29]	Risk Ratio IV, Random, 95% Cl
Study or Subgroup 1.2.1 Community mo Azad 2010 Manandhar 2004 More 2012 Tripathy 2010 Subtotal (95% CI) Heterogeneily: Tau <sup>2</sup> = Test for overall effect: 1.2.2 Home visitation Bari 2006 Darmstadt 2010 Kirkwood 2013 Subtotal (95% CI) Heterogeneily: Tau <sup>2</sup> = Test for overall effect: 1.2.3 Community mo Kumar 2008 (1) Kumar 2008 (2) Subtotal (95% CI) Heterogeneily: Tau <sup>2</sup> = Test for overall effect: 1.2.3 Community mo	log[Risk Ratio]           bilization           -0.1165           0.6097           -0.0834           0.4253           0.15; Chi <sup>#</sup> = 28.1           Z = 0.87 (P = 0.38           0.5785           0.4263           0.5785           0.4804           0.3577           0.00; Chi <sup>#</sup> = 2.38           Z = 7.96 (P < 0.00	In SE 0.1153 0.1073 0.118 0.3503 1, df = 3 (P 0.1002 0.0835 0.1024 , df = 2 (P = 0001) visitation 0.0816 0.0803 , df = 1 (P = 004)	tervention ( Total 4457 2823 2590 940 10810 < 0.00001); F 270 355 102 727 727 0.30); F = 18 1522 1087 2609 : 0.0009); F = 8	Control Total 4441 3107 2566 1050 11164 *= 89% 257 400 77 734 % 540 1079 66%	Weight 10.2% 10.4% 10.1% 4.4% 35.1% 10.6% 11.1% 10.6% 32.3% 11.1% 22.2%	Risk Ratio IV, Random, 95% CI 0.89 [0.71, 1.12] 1.84 [1.49, 2.27] 0.92 [0.73, 1.16] 1.53 [0.77, 3.04] 1.20 [0.79, 1.83] 1.78 [1.47, 2.17] 1.62 [1.37, 1.90] 1.43 [1.17, 1.75] 1.61 [1.43, 1.81] 1.47 [1.25, 1.72] 1.99 [1.70, 2.32] 1.71 [1.27, 2.29]	Risk Ratio IV, Random, 95% Cl
Study or Subgroup 1.2.1 Community mo Azad 2010 Manandhar 2004 More 2012 Tripathy 2010 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 1.2.2 Home visitation Bari 2006 Darmstadt 2010 Kirkwood 2013 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 1.2.3 Community mo Kumar 2008 (1) Kumar 2008 (2) Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 1.2.4 Enhanced perint	log[Risk Ratio]           bilization         -0.1165           0.6097         -0.0834           0.4253         0.4253           :0.15; Chi <sup>2</sup> = 28.1         Z = 0.87 (P = 0.38           0.5785         0.4804           0.3577         :0.3677           :0.00; Chi <sup>2</sup> = 2.38         Z = 7.96 (P < 0.00	In SE 0.1153 0.1073 0.1183 0.1073 0.118 0.3503 1, df = 3 (P 3) 0.1002 0.0835 0.1024 0.0816 0.0816 0.0816 0.0833 df = 1 (P = 004) ion	tervention 0 Total 4457 2823 2590 940 10810 < 0.00001); F 270 355 102 727 0.30); F= 16 1522 1087 2609 : 0.009); F = 8	Control Total 4441 3107 2566 1050 11164 *= 89% 257 400 77 734 ** ** ** ** ** ** ** ** ** **	Weight 10.2% 10.4% 10.4% 35.1% 10.6% 11.1% 32.3% 11.1% 11.1% 22.2%	Risk Ratio IV, Random, 95% CI 0.89 [0.71, 1.12] 1.84 [1.49, 2.27] 0.92 [0.73, 1.16] 1.53 [0.77, 3.04] 1.20 [0.79, 1.83] 1.78 [1.47, 2.17] 1.62 [1.37, 1.90] 1.43 [1.37, 1.90] 1.43 [1.17, 1.75] 1.61 [1.43, 1.81] 1.47 [1.25, 1.72] 1.99 [1.70, 2.32] 1.71 [1.27, 2.29]	Risk Ratio IV, Random, 95% Cl
Study or Subgroup 1.2.1 Community mo Azad 2010 Manandhar 2004 More 2012 Tripathy 2010 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 1.2.2 Home visitation Bari 2006 Darmstadt 2010 Kirkwood 2013 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 1.2.3 Community mo Kumar 2008 (1) Kumar 2008 (2) Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 1.2.4 Enhanced perin Sloan 2008	log[Risk Ratio]           bilization         -0.1165           0.6097         -0.0834           0.4253         0.15; Chi <sup>2</sup> = 28.1 $Z = 0.87$ (P = 0.38         0.5785           0.4804         0.3577           0.00; Chi <sup>2</sup> = 2.38         Z = 7.96 (P < 0.00)	In SE 0.1153 0.1073 0.118 0.3503 1, df = 3 (P 0.1002 0.0835 0.1024 df = 2 (P = 0.001) visitation 0.0803 0.1024 df = 1 (P = 0.04) on 0.1094	tervention ( Total 4457 2823 2590 940 10810 < 0.00001); F 270 365 102 270 365 102 102 1030; F = 16 1522 1087 2609 < 0.0009); F = 8 1970	Control Total 4441 3107 2566 1050 11164 *= 89% 257 400 77 734 % 539 540 1079 56% 1913	Weight 10.2% 10.4% 10.1% 35.1% 10.6% 32.3% 11.1% 11.1% 22.2% 10.4%	Risk Ratio IV, Random, 95% CI 0.89 [0.71, 1.12] 1.84 [1.49, 2.27] 0.92 [0.73, 1.16] 1.53 [0.77, 3.04] 1.20 [0.79, 1.83] 1.78 [1.47, 2.17] 1.62 [1.37, 1.90] 1.43 [1.17, 1.75] 1.61 [1.43, 1.81] 1.47 [1.25, 1.72] 1.99 [1.70, 2.32] 1.71 [1.27, 2.29] 1.05 [0.95, 1.30]	Risk Ratio IV, Random, 95% Cl
Study or Subgroup 1.2.1 Community mo Azad 2010 Manandhar 2004 More 2012 Tripathy 2010 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 1.2.2 Home visitation Bari 2006 Darmstadt 2010 Kirkwood 2013 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 1.2.3 Community mo Kumar 2008 (2) Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 1.2.4 Enhanced perin Sloan 2008 Subtotal (95% CI)	log[Risk Ratio]           bilization           -0.1165           0.6097           -0.0834           0.4253           0.15; Chi <sup>2</sup> = 28.1           Z = 0.87 (P = 0.38           0.5785           0.4804           0.3577           0.00; Chi <sup>2</sup> = 2.38           Z = 7.96 (P < 0.00	In SE 0.1153 0.1073 0.118 0.3503 1, df = 3 (P 3) 0.1002 0.0835 0.1024 , df = 2 (P = 0.0803 0.1024 , df = 2 (P = 0.0803 0.0803 0.0803 , df = 1 (P = 0.04) ion 0.1094	tervention ( Total 4457 2823 2650 940 10810 < 0.00001); F 2700 355 102 727 0.30); I <sup>2</sup> = 16 1522 1087 2609 0.0009); I <sup>2</sup> = 6 1970 1970	Control Total 4441 3107 2566 1050 11164 *= 89% 267 400 77 734 % 539 540 1079 66%	Weight 10.2% 10.4% 10.1% 4.4% 35.1% 10.6% 11.1% 10.6% 32.3% 11.1% 11.1% 22.2% 10.4% 10.4%	Risk Ratio IV, Random, 95% CI 0.89 [0.71, 1.12] 1.84 [1.49, 2.27] 0.92 [0.73, 1.16] 1.53 [0.77, 3.04] 1.20 [0.79, 1.83] 1.78 [1.47, 2.17] 1.62 [1.37, 1.90] 1.43 [1.17, 1.75] 1.61 [1.43, 1.81] 1.47 [1.25, 1.72] 1.99 [1.70, 2.32] 1.71 [1.27, 2.29] 1.05 [0.85, 1.30]	Risk Ratio IV, Random, 95% Cl
Study or Subgroup 1.2.1 Community mo Azad 2010 Manandhar 2004 More 2012 Tripathy 2010 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 1.2.2 Home visitation Bari 2006 Darmstadt 2010 Kirkwood 2013 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 1.2.3 Community mo Kumar 2008 (1) Kumar 2008 (2) Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 1.2.4 Enhanced perint Sloan 2008 Subtotal (95% CI) Heterogeneity: Not ag	log[Risk Ratio]           bilization         -0.1165           0.6097         -0.0834           0.4253         0.4253           : 0.15; Chi <sup>2</sup> = 28.1         Z           Z = 0.87 (P = 0.36         0.404           0.3577         0.30577           : 0.00; Chi <sup>2</sup> = 2.38         Z           Z = 7.96 (P < 0.00	In SE 0.1153 0.1073 0.1183 0.3503 1, df = 3 (P 3) 0.1002 0.0835 0.1024 0.0835 0.1024 (df = 2 (P = 0001) visitation 0.0816 0.0803 , df = 1 (P = 004) ion 0.1094	tervention 0 Total 4457 2823 2590 940 10810 < 0.00001); F 270 355 102 727 0.30); F= 16 1522 1087 2609 : 0.009); F= 8 1970 1970	Control Total 4441 3107 2566 1050 11164 *= 89% 257 400 77 734 ** \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	Weight 10.2% 10.4% 10.4% 35.1% 10.6% 11.1% 32.3% 11.1% 11.1% 11.1% 11.1% 10.4% 10.4%	Risk Ratio IV, Random, 95% CI 0.89 [0.71, 1.12] 1.84 [1.49, 2.27] 0.92 [0.73, 1.16] 1.53 [0.77, 3.04] 1.20 [0.79, 1.83] 1.78 [1.47, 2.17] 1.62 [1.37, 1.90] 1.43 [1.71, 1.75] 1.61 [1.43, 1.81] 1.61 [1.43, 1.81] 1.47 [1.25, 1.72] 1.99 [1.70, 2.32] 1.71 [1.27, 2.29] 1.05 [0.85, 1.30] 1.05 [0.85, 1.30]	Risk Ratio IV, Random, 95% Cl
Study or Subgroup 1.2.1 Community mo Azad 2010 Manandhar 2004 More 2012 Tripathy 2010 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 1.2.2 Home visitation Bari 2006 Darmstadt 2010 Kirkwood 2013 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 1.2.3 Community mo Kumar 2008 (1) Kumar 2008 (2) Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 1.2.4 Enhanced perin Sloan 2008 Subtotal (95% CI) Heterogeneity: Not ag Test for overall effect:	log[Risk Ratio]           bilization         -0.1165           0.6097         -0.0834           0.4253         0.4253           : 0.15; Chi <sup>2</sup> = 28.1         Z           Z = 0.87 (P = 0.38         0.4804           0.3577         0.4804           0.3577         0.4804           0.3577         0.00; Chi <sup>2</sup> = 2.38           Z = 7.96 (P < 0.00)	In SE 0.1153 0.1073 0.118 0.3503 1. df = 3 (P 0.1002 0.0835 0.1024 0.0835 0.1024 df = 2 (P = 0.001) visitation 0.0803 0.0803 df = 1 (P = 0.04) ion 0.1094 (P)	tervention ( Total 4457 2823 2590 940 10810 < 0.00001); F 270 365 102 270 365 102 102 103 102 103 103 103 102 103 103 103 103 103 103 103 103	Control Total 4441 3107 2566 1050 11164 *= 89% 257 400 77 734 % 539 540 1079 56% 1913 1913	Weight 10.2% 10.4% 10.1% 4.4% 35.1% 10.6% 32.3% 11.1% 22.2% 10.4% 10.4%	Risk Ratio IV, Random, 95% CI 0.89 [0.71, 1.12] 1.84 [1.49, 2.27] 0.92 [0.73, 1.16] 1.53 [0.77, 3.04] 1.20 [0.79, 1.83] 1.78 [1.47, 2.17] 1.62 [1.37, 1.90] 1.43 [1.17, 1.75] 1.61 [1.43, 1.81] 1.47 [1.25, 1.72] 1.99 [1.70, 2.32] 1.71 [1.27, 2.29] 1.05 [0.85, 1.30] 1.05 [0.85, 1.30]	Risk Ratio IV, Random, 95% Cl
Study or Subgroup 1.2.1 Community mo Azad 2010 Manandhar 2004 More 2012 Tripathy 2010 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 1.2.2 Home visitation Bari 2006 Darmstadt 2010 Kirkwood 2013 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 1.2.3 Community mo Kumar 2008 (1) Kumar 2008 (2) Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 1.2.4 Enhanced perin Sloan 2008 Subtotal (95% CI) Heterogeneity: Not ag Test for overall effect:	log[Risk Ratio]           bilization           -0.1165           0.6097           -0.0834           0.4253           0.15; Chi² = 28.1           Z = 0.87 (P = 0.38           0.5785           0.4804           0.3577           0.00; Chi² = 2.38           Z = 7.96 (P < 0.00	In SE 0.1153 0.1073 0.118 0.3503 1, df = 3 (P 0.0835 0.1002 0.0835 0.1024 , df = 2 (P = 0.0803 0.1024 visitation 0.0803 , df = 1 (P = 004) ion 0.1094 3)	tervention ( Total 4457 2823 2630 940 10810 < 0.00001); F 2770 355 102 727 0.300; I* = 16 1522 1087 2609 0.0009); I* = 6 1970 1970	Control Total 4441 3107 2566 1050 11164 *= 89% 267 4000 77 734 539 540 1079 56%	Weight 10.2% 10.4% 10.1% 4.4% 35.1% 10.6% 11.1% 10.6% 32.3% 11.1% 11.1% 22.2% 10.4% 10.4%	Risk Ratio IV, Random, 95% CI 0.89 [0.71, 1.12] 1.84 [1.49, 2.27] 0.92 [0.73, 1.16] 1.53 [0.77, 3.04] 1.20 [0.79, 1.83] 1.78 [1.47, 2.17] 1.62 [1.37, 1.90] 1.43 [1.17, 1.75] 1.61 [1.43, 1.81] 1.47 [1.25, 1.72] 1.99 [1.70, 2.32] 1.71 [1.27, 2.29] 1.05 [0.85, 1.30] 1.05 [0.85, 1.30]	Risk Ratio IV, Random, 95% Cl
Study or Subgroup 1.2.1 Community mo Azad 2010 Manandhar 2004 More 2012 Tripathy 2010 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 1.2.2 Home visitation Bari 2006 Darmstadt 2010 Kirkwood 2013 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 1.2.3 Community mo Kumar 2008 (1) Kumar 2008 (2) Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 1.2.4 Enhanced perint Sloan 2008 Subtotal (95% CI) Heterogeneity: Not ag Test for overall effect: Total (95% CI)	log[Risk Ratio]           bilization         -0.1165           0.6097         -0.0834           0.4253         0.4253           :0.15; Chi <sup>2</sup> = 28.1         Z           Z = 0.87 (P = 0.36         0.404           0.3577         0.400; Chi <sup>2</sup> = 2.38           Z = 7.96 (P < 0.00	In SE 0.1153 0.1073 0.1183 0.3503 1, df = 3 (P 3) 0.1002 0.0835 0.1024 0.0816 0.0816 0.0816 0.0826 0.0833 df = 1 (P = 004) ion 0.1094 3)	tervention ( Total 4457 2823 2590 940 10810 < 0.00001); F 270 355 102 727 0.30); F= 16 1522 1087 2609 : 0.009); F= 8 1970 1970 1970 1970	Control Total 4441 3107 2566 1050 11164 *= 89% 257 400 77 734 ** 539 540 1079 16% 1913 1913 1913	Weight 10.2% 10.4% 10.4% 35.1% 10.6% 11.1% 10.6% 11.1% 11.1% 11.1% 11.1% 10.4% 10.4% 10.4%	Risk Ratio IV, Random, 95% CI 0.89 [0.71, 1.12] 1.84 [1.49, 2.27] 0.92 [0.73, 1.16] 1.53 [0.77, 3.04] 1.20 [0.79, 1.83] 1.78 [1.47, 2.17] 1.62 [1.37, 1.90] 1.43 [1.71, 1.75] 1.61 [1.43, 1.81] 1.61 [1.43, 1.81] 1.47 [1.25, 1.72] 1.99 [1.70, 2.32] 1.71 [1.27, 2.29] 1.05 [0.85, 1.30] 1.05 [0.85, 1.30] 1.05 [0.85, 1.30]	Risk Ratio IV, Random, 95% Cl
Study or Subgroup 1.2.1 Community mo Azad 2010 Manandhar 2004 More 2012 Tripathy 2010 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 1.2.2 Home visitation Bari 2006 Darmstadt 2010 Kirkwood 2013 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 1.2.3 Community mo Kumar 2008 (1) Kumar 2008 (2) Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 1.2.4 Enhanced perin Sloan 2008 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> =	log[Risk Ratio]           bilization         -0.1165           0.6097         -0.0834           0.4253         0.4253           : 0.15; Chi <sup>2</sup> = 28.1         Z           Z = 0.87 (P = 0.36         0.4804           0.3577         0.4804           0.3577         0.4804           0.3577         0.4004           0.3577         0.00; Chi <sup>2</sup> = 2.38           Z = 7.96 (P < 0.00	In SE 0.1153 0.1073 0.118 0.3503 1. df = 3 (P 0.1002 0.0835 0.1024 0.0835 0.1024 df = 2 (P = 0001) visitation 0.08036 0.08036 0.08035 0.1024 visitation 0.08036 0.08036 0.08037 0.1094 0.1094 (b) (c) (c) (c) (c) (c) (c) (c) (c	tervention ( Total 4457 2823 2590 940 10810 < 0.00001); F 270 365 102 270 365 102 1087 2609 0.0009); F = 16 1522 1087 2609 0.0009); F = 16 1970 19	Control Total 4441 3107 2566 1050 11164 *= 89% 257 400 77 734 % 539 540 1079 56% 1913 1913 1913 1913 1913	Weight 10.2% 10.4% 10.1% 4.4% 35.1% 10.6% 32.3% 11.1% 11.1% 22.2% 10.4% 10.4% 10.4% 10.0%	Risk Ratio IV, Random, 95% CI 0.89 [0.71, 1.12] 1.84 [1.49, 2.27] 0.92 [0.73, 1.16] 1.53 [0.77, 3.04] 1.20 [0.79, 1.83] 1.78 [1.47, 2.17] 1.62 [1.37, 1.90] 1.43 [1.17, 1.75] 1.61 [1.43, 1.81] 1.47 [1.25, 1.72] 1.99 [1.70, 2.32] 1.71 [1.27, 2.29] 1.05 [0.85, 1.30] 1.05 [0.85, 1.30] 1.40 [1.17, 1.68]	Risk Ratio IV, Random, 95% Cl

Test for overall effect: Z = 3.70 (P = 0.0002) Test for subgroup differences: Chi<sup>a</sup> = 13.57, df = 3 (P = 0.004), i<sup>a</sup> = 77.9% <u>Footnotes</u> (1) Essential Newborn Care (2) Essential Newborn Care + thermo spot

Fig. 1. Health care seeking for maternal and ewborn illnesses: intensity of intervention.

funds for emergency transportation, it showed no impact on improving maternal health care seeking (RR 0.88; 95% CI: 0.75–1.03, 1 study, n = 2,561) (Fig. 1a and b).

Based on strategies used for enhancing health care seeking, community mobilization alone showed no improvement in health care seeking for maternal illnesses (RR 1.05; 95% CI: 0.77–1.45, 3 studies, n = 11,144) or neonatal illnesses (RR 1.20; 95% CI: 0.79–1.83, 4 studies, n = 21,974,). Home visiting by CHWs alone had a

significant impact on improving health care seeking for neonatal illnesses (RR 1.61; 95% CI: 1.43–1.81; 3 studies, n = 1,461), but no impact was seen for maternal illnesses (RR 0.96; 95% CI: 0.83–1.12, 1 study, n = 876). When home visiting was combined with community mobilization, significant improvements were seen for both maternal illnesses (RR 1.15; 95% CI: 1.11–1.20; 1 study, n = 3,810) and newborn illnesses (RR 1.71; 95% CI: 1.27–2.29; 1 study, n = 3,688) (Fig. 2a and b). Estimates from non-RCTs

## 2.1 Health care seeking for maternal illnesses



Fig. 2. Health care seeking for maternal and newborn illnesses: strategies for delivering interventions.

found no impact on improving health care seeking for neonatal illnesses (Table 2). However, results from beforeafter studies were similar to the results from RCTs showing no impact on health care seeking for maternal illnesses RR 1.13; 95% CI: 0.86–1.48; 1 study, n = 1,443 but significant improvement in health care seeking for neonatal illnesses (RR 1.35; 95% CI: 1.19–1.53; 4 studies, n = 4,348) (Table 3).

## Mortality outcomes

RCTs included in this review displayed a non-significant borderline reduction in maternal mortality (RR 0.80; 95% CI: 0.65–1.00; 8 studies, n = 114,196) (Table 1). However, significant impact was observed on total neonatal mortality (RR 0.80; 95% CI: 0.72–0.89; 21 studies, n = 248,848) (Supplementary File 2) including both early (RR 0.70; 95% CI: 0.61–0.81; 11 studies, n = 113,147) and late neonatal mortality (RR 0.77; 95% CI: 0.6–0.93; 9 studies, n = 108,359) (Table 1). Impact was also significant for reducing perinatal mortality (RR 0.84; 95% CI: 0.78–0.90; 16 studies, n = 279,618) and stillbirths (RR 0.82; 95% CI: 0.74–0.92; 12 studies, n = 176,683) (Table 1). On GRADE analysis, evidence was moderate for maternal

Outcomes	Summary estimates	Number of studies and participants	Heterogeneity
Primary outcomes			
Health care seeking for neonatal	RR 0.96; 95% Cl: 0.71, 1.31	3 ( <i>n</i> = 2,103)	$\tau^2$ 0.09; $\chi^2 P < 0.00001$ ; $I^2$ 94%
illnesses			
Secondary outcomes			
Mortality outcomes			
Maternal mortality	RR 0.97; 95% CI: 0.64, 1.49	5 ( <i>n</i> = 119,078)	$\tau^2$ 0.19; $\chi^2 P < 0.00001$ ; $l^2$ 89%
Neonatal mortality	RR 0.83; 95% Cl: 0.54, 1.26	4 ( <i>n</i> = 28,641)	τ <sup>2</sup> 0.13; χ <sup>2</sup> <i>P</i> =0.004; <i>I</i> <sup>2</sup> 77%
Early neonatal mortality	RR 0.57; 95% Cl: 0.30, 1.09	2 (n = 3,921)	τ <sup>2</sup> 0.10; χ <sup>2</sup> <i>P</i> =0.19; <i>I</i> <sup>2</sup> 41%
Late neonatal mortality	RR 0.84; 95% Cl: 0.12, 5.80	2 (n = 3,921)	τ <sup>2</sup> 1.55; χ <sup>2</sup> <i>P</i> =0.03; <i>I</i> <sup>2</sup> 79%
Stillbirths	RR 0.97; 95% Cl: 0.71, 1.34	3 (n = 6,096)	$\chi^2 P = 0.01; I^2 77\%$
Perinatal mortality	RR 0.74; 95% Cl: 0.44, 1.23	4 ( <i>n</i> = 101,834)	$\tau^2$ 0.22; $\chi^2 P < 0.00001$ ; $l^2$ 89%
Morbidity outcomes			
Any perceived neonatal illnesses	RR 1.12; 95% CI: 0.90, 1.39	1 ( <i>n</i> = 459)	
Process outcomes			
Any antenatal care	RR 1.05; 95% CI: 1.04, 1.06	3 (n = 31,305)	$\chi^2 P < 0.00001; I^2 98\%$
Iron/folate supplementation	RR 24.53; 95% CI: 13.20, 45.59	1 ( <i>n</i> = 756)	_
Birthing by skilled birth attendant	RR 1.03; 95% CI: 0.97, 1.10	1 ( <i>n</i> = 13,826)	_
Institutional births	RR 1.89; 95% CI: 1.48, 2.41	2 (n = 2,291)	$\tau^2$ 0.03; $\chi^2 P < 0.00001$ ; $l^2$ 86%
Initiation of breastfeeding within	RR 6.54; 95% CI: 5.88, 7.27	1 ( <i>n</i> = 13,826)	_
an hour of birth			

## Table 2. Results from non-randomized controlled trials

Significant estimates are provided in BOLD.

mortality; however, it was high quality for the rest of the other mortality outcomes (Fig. 3).

Based on intensity of interventions and strategies used within RCTs, no differences were seen for reducing maternal mortality (Table 4). Community mobilization alone showed a significant impact on reducing neonatal mortality (RR 0.79; 95% CI: 0.70–0.89; 10 studies, n = 123,047); however, home visitation alone showed no impact (RR 0.87; 95% CI: 0.57–1.32; 4 studies, n = 21,214). Community mobilization and home visitation in combination showed a significant impact on reducing neonatal mortality (RR 0.73; 95% CI: 0.71–0.89; 4 studies,

Table 3. Results from before/after studies

Outcomes	Summary estimates	Number of studies and participants	Heterogeneity
Primary outcomes			
Health care seeking for maternal illnesses	RR 1.13; 95% Cl: 0.86, 1.48	1 ( <i>n</i> = 1,443)	_
Health care seeking for neonatal illnesses	RR 1.35; 95% CI: 1.19, 1.53	4 ( <i>n</i> = 4,348)	τ <sup>2</sup> 0.01; χ <sup>2</sup> <i>P</i> =0.003; <i>I</i> <sup>2</sup> 75%
Secondary outcomes			
Mortality outcomes			
Neonatal mortality	RR 0.55; 95% Cl: 0.18, 1.73	2 ( <i>n</i> = 60,762)	τ <sup>2</sup> 0.66; χ <sup>2</sup> <i>P</i> < 0.00001; <i>I</i> <sup>2</sup> 98%
Early neonatal mortality	RR 1.53; 95% Cl: 0.78, 3.01	3 ( <i>n</i> = 3,418)	τ <sup>2</sup> <i>P</i> 0.26; χ <sup>2</sup> <i>P</i> =0.004; <i>I</i> <sup>2</sup> 82%
Stillbirths	RR 0.70; 95% CI: 0.60, 0.82	4 ( <i>n</i> = 61,176)	χ <sup>2</sup> Ρ 0.03; <i>Ι</i> <sup>2</sup> 65%
Perinatal mortality	RR 0.96; 95% CI: 0.85, 1.09	4 ( <i>n</i> = 60,944)	χ <sup>2</sup> <i>P</i> < 0.00001; <i>I</i> <sup>2</sup> 90%
Process outcomes			
Any antenatal care	RR 1.27; 95% CI: 1.24, 1.30	3 ( <i>n</i> = 10,137)	$\chi^2 P < 0.00001; I^2 98\%$
Iron/folate supplementation	RR 1.29; 95% CI: 1.25, 1.33	1 ( <i>n</i> = 3,480)	_
Any tetanus toxoid immunization	RR 1.14; 95% CI: 1.10, 1.17	1 ( <i>n</i> = 3,480)	
Institutional births	RR 32.76; 95% CI: 0.04, 29028.97	2 ( <i>n</i> = 5,859)	$\tau^2 = 23.02;  \chi^2  P < 0.00001;  l^2  96\%$
Initiation of breastfeeding within an hour of birth	RR 1.54; 95% Cl: 0.97, 2.44	2(n = 2,474)	$\tau^2 = 0.11;  \chi^2  P < 0.00001;  l^2  99\%$

Significant estimates are provided in BOLD.

#### RCTs for maternal and newborn health

Patient or population: patients with maternal and newborn health

Settings: Intervention: RCTs

Outcomes	Illustrative com	parative risks* (95% CI)	Relative effect	No of Participants	Quality of the evidence	Comments
	Assumed risk Control	Corresponding risk RCTs	(95% CI)	(studies)	(GRADE)	
Maternal care seeking - from skilled care provider	274 per 1000	290 per 1000 (252 to 334)	RR 1.06 (0.92 to 1.22)	15828 (5 studies)	⊕⊕⊕⊜ moderate <sup>1</sup>	
Neonatal care seeking - from skilled care provider	92 per 1000	128 per 1000 (107 to 154)	RR 1.4 (1.17 to 1.68)	25850 (8 studies)	⊕⊕⊕⊕ high	
Maternal mortality	3 per 1000	3 per 1000 (2 to 3)	RR 0.80 (0.65 to 1.00)	113938 (8 studies)	⊕⊕⊕⊕ high	
Neonatal mortality	34 per 1000	27 per 1000 (24 to 30)	RR 0.79 (0.71 to 0.89)	248848 (20 studies)	⊕⊕⊕⊕ high	
Stillbirths	25 per 1000	21 per 1000 (19 to 24)	RR 0.82 (0.73 to 0.93)	154122 (11 studies)	⊕⊕⊕⊕ high	
Perinatal mortality	42 per 1000	35 per 1000 (32 to 38)	RR 0.84 (0.77 to 0.90)	257057 (15 studies)	⊕⊕⊕⊕ high	

\*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio;

GRADE Working Group grades of evidence

High quality: Further research is very unlikely to change our confidence in the estimate of effect.

Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate

Very low quality: We are very uncertain about the estimate.

<sup>1</sup> One of the included study provided single intervention, while rest provided package of interventions. On the other hand, the strategies with which intervention was delivered was different in all the studies.

## Fig. 3. GRADE analysis.

n = 114,509), and enhanced perinatal care/education showed no impact (RR 0.90; 95% CI: 0.57-1.41; 4 studies, n = 12,455). Community mobilization alone (RR 0.69; 95% CI: 0.57–0.82; 6 studies, *n* = 73,288) and community mobilization in combination with home visitation (RR 0.69; 95% CI: 0.54–0.88; 3 studies, n = 32,263) showed a significant impact on reducing early neonatal mortality (ENM): however, enhanced perinatal care/education alone had no impact (RR 0.81; 95% CI: 0.44-1.50; 2 studies, n = 7,569). Community mobilization in combination with home visitation also showed significant impact on reducing late neonatal mortality (RR 0.61; 95% CI: 0.41-0.92; 3 studies, n = 32,263), however, community mobilization (RR 0.83; 95% CI: 0.67–1.03; 5 studies, n = 71,931) together with enhanced perinatal care/education showed no impact (RR 1.09; 95% CI: 0.55-2.18; 1 study, n = 4,165). Community mobilization in combination with home visitation (RR 0.78; 95% CI: 0.71-0.86; 2 studies, n = 33,786) and enhanced perinatal care/education (RR 0.62; 95% CI: 0.49–0.79; 2 studies, n = 6,251) showed a significant impact on reducing stillbirths, however, community mobilization alone showed no impact (RR 0.94; 95% CI: 0.83–1.06; 7 studies, *n* = 136,646). Community mobilization in combination with home visitation (RR 0.78; 95% CI: 0.68–0.89; 5 studies, *n* = 100,553) and community mobilization alone (RR 0.88; 95% CI: 0.82-0.95; 10 studies, n = 205,843) showed a significant impact on reducing stillbirths, however, enhanced perinatal care/ education alone showed no impact (RR 0.84; 95% CI: 0.61-1.16; 3 studies, n = 27,326) (Table 4).

Subgroup analyses based on intensity of interventions showed birth preparedness alone had no impact on improving neonatal mortality (RR 0.91; 95% CI: 0.76–1.09; 11 studies, n = 129,937), however, when birth preparedness was paired with recognition and referrals (RR

0.73; 95% CI: 0.60–0.88; 8 studies, n = 105,846) and then with funds for emergency transportation (RR 0.78; 95% CI: 0.70–0.87; 2 studies, n = 29,927) there was a significant impact on reducing neonatal mortality. Similarly, birth preparedness alone showed no impact on improving late neonatal mortality (RR 0.85; 95% CI: 0.70-1.04; 6 studies, n = 76,096), however, when birth preparedness was paired with recognition and referrals (RR 0.40; 95% CI: 0.24-0.68; 1 study, n = 3,688) there was a significant impact on reducing late neonatal mortality. When funds for emergency transportation was combined with birth preparedness and recognition and referrals (RR 0.80; 95% CI: 0.70-0.87; 2 studies, n = 29,927). Birth preparedness alone showed a significant impact on reducing ENM and stillbirths (ENM RR 0.79; 95% CI: 0.66-0.95; 6 studies, n = 75,196; stillbirths RR 0.85; 95% CI: 0.74–0.96; 10 studies, n = 171,703; it also showed an impact on these outcomes when paired with recognition of complication and referrals (ENM RR 0.55; 95% CI: 0.43-0.71; 2 studies, *n* = 7,119; stillbirths RR 0.72; 95% CI: 0.61–0.84; 3 studies, n = 4,980) and funds for emergency transportation (ENM RR 0.66; 95% CI: 0.50–0.88; 3 studies, n = 30,832; stillbirths RR 0.78; 95% CI: 0.70-0.87; 2 studies, n = 29,927). Birth preparedness alone (RR 0.91; 95% CI: 0.84–0.98; 9 studies, n = 149,097) and in combination to recognition and referrals (RR 0.75; 95% CI: 0.64-0.89; 5 studies, n = 93,665) showed significant impact on reducing perinatal mortality, however when further intensified and paired with funds for emergency transportation (RR 0.81; 95% CI: 0.64–1.01; 3 studies, n = 32,184), there was no impact on reducing perinatal mortality (Table 4).

From non-RCTs (Table 2) and before-after studies (Table 3), significant reductions in stillbirths were observed

Strategies employed					
	Community mobilization	Home visitation	Community mobilization and home visitation	Enhanced perinatal care/education	Subgroup differences (P value of Chi <sup>2</sup> )
Maternal mortality	RR 0.81 95% CI: 0.54, 1.21 6 studies, <i>n</i> = 79,203	RR 0.62; 95% CI: 0.35, 1.09 2 studies, <i>n</i> = 10,021	RR 0.82; 95% Cl: 0.46, 1.46 1 study, <i>n</i> = 6,230	RR 0.74; 95% Cl: 0.45, 1.22 1 study, <i>n</i> = 18,699	P=0.16
Neonatal mortality	τ <sup>±</sup> 0.13, χ <sup>±</sup> P=0.04; μ <sup>*</sup> 56% RR 0.79; 95% CI: 0.70, 0.89 10 studies, n = 123,047 -² 0.03,² b = 0.0001, ι² 74%	で 0.00;	RR 0.73; 95% CI: 0.71, 0.89 4 studies, n = 114,509 -² o.oc² b _ o. 74, i² soo.	RR 0.90; 95% CI: 0.57, 1.41 4 studies, <i>n</i> =12,455 -2 o to: -2 <i>n</i> -00001, <i>P</i> 0402	P=0.78
Early neonatal mortality	<sup>c</sup> 0.003, <i>X</i> Γ = 0.0001,1 / 1.1% RR 0.69; 95% CI: 0.57, 0.82 6 studies, n = 73,288 r² <sup>2</sup> ∩ ∩6- v² D ∨ ∩ ∩∩∩01-1 <sup>2</sup> 81%		голо; Хг = си.г.н. гос. RR 0.69; 95% СІ: 0.54, 0.38 3 studies, n = 32,263 -² ∩ ли. √² р – ∩ лэ- г² сем.	r 0.19, X T < 0.0001,1 94% RR 0.81; 95% CI: 0.44, 1.50 2 studies, <i>n</i> = 7,596 - <sup>2</sup> 0.14 <sup>. , 2</sup> P = 0.01 <sup>. f<sup>2</sup></sup> 7.0%	P <0.0001
Late neonatal mortality	RR 0.83; 95% Cl: 0.67, 1.03 5 studies, $n = 71$ , 931 $\tau^2$ 0.02; $\chi^2 P = 0.22$ ; $l^2$ 31% P = 0.28	1	RR 0.61; 95% CI: 0.41, 0.92 3 studies, n =32,263 τ² 0.10; χ² P = 0.04; Ι² 63%	RR 1.09; 95% CI: 0.55, 2.18 1 study, n4,165	
Stillbirths	RR 0.94; 95% CI: 0.83, 1.06 7 studies, <i>n</i> = 136,646 τ <sup>2</sup> 0.01; <i>γ</i> <sup>2</sup> <i>P</i> = 0.09; <i>β</i> 45%	I	RR 0.78; 95% CI: 0.71, 0.86 2 studies, n =33,786 r <sup>2</sup> 0.00; y <sup>2</sup> P =0.74; I <sup>2</sup> 0%	RR 0.62; 95% CI: 0.49, 0.79 2 studies, n =6,251 ⁺² 0.01; ½ P =0.16; l² 50%	P = 0.004
Perinatal mortality	RR 0.88; 95% CI: 0.82, 0.95 10 studies, n = 205,843 r² 0.01; ½ P = 0.08; l² 41%	RR 0.82; 95% CI: 0.62, 1.08 1 study, <i>n</i> =6,376	RR 0.78; 95% CI: 0.68, 0.89 5 studies, n = 100,553 τ <sup>2</sup> 0.02; χ <sup>2</sup> P = 0.002; l <sup>2</sup> 73%	RR 0.84; 95% CI: 0.61, 1.16 3 stucies, $n = 27,326$ $\tau^2$ 0.07; $\chi^2 P = 0.005; P$ 88%	P=0.41
Intensity of intervention	Rinth meanarachasse	Birth preparedness + reconsition and referrals	Birth preparedness + recognition and referrals + Funds for emergency transportation		
Maternal mortality	RR 0.81 95% Cl: 0.54, 1.21 6 studies, <i>n</i> = 80,040	RR 0.73; 95% Cl: 0.51, 1.05 3 studies, <i>n</i> = 29,454			P=0.71
Neonatal mortality	$\tau^2$ 0.13; $\gamma^2$ P = 0.04; $l^2$ 56% RR 0.91; 95% CI: 0.76, 1.09 11 studies, $n = 129,937$ $\tau^2$ 0.08; $\gamma^2$ P <0.00001; $l^2$ 85%	τ <sup>2</sup> 0.00; χ <sup>2</sup> P = 0.63; l <sup>2</sup> 0% RR 0.73; 95% CI: 0.60, 0.88* 8 studies, n = 105,846 τ <sup>2</sup> 0.07; χ <sup>2</sup> P <0.00001; l <sup>2</sup> 79%	RR 0.78; 95% CI: 0.70, 0.87 2 studies, n = 29,927 τ <sup>2</sup> 0.03; χ <sup>2</sup> P = 0.0001; 1 <sup>2</sup> 0%		P=0.11

Table 4. Mortality outcomes based on intensity of interventions and strategies employed

		Birth preparedness	Birth preparedness + recognition and referrals	
	Birth preparedness	+ recognition and referrals	+ Funds for emergency transportation	
Early neonatal mortality	RR 0.79; 95% CI: 0.66, 0.95	RR 0.55; 95% CI: 0.43, 0.71	RR 0.66; 95% CI: 0.50, 0.88	P=0.06
	6 studies, n <i>=</i> 75,196	2 studies, $n = 7,119$	3  studies, n=30,832	
	$ au^2$ 0.03; $\chi^2$ P = 0.010; l <sup>2</sup> 67%	$ au^2$ 0.00; $\chi^2$ P = 0.98; l <sup>2</sup> 0%	$ au^2$ 0.08; $\chi^2$ P < 0.0001; l <sup>2</sup> 90%	
Late neonatal mortality	RR 0.85; 95% CI: 0.70, 1.04	RR 0.40; 95% CI: 0.24, 0.68	RR 0.80; 95% CI: 0.60, 1.06	P = 0.03
	6 studies, $n = 76,096$	1 study, n =3,688	2 studies, $n = 28,575$	
	$\tau^2$ 0.01; $\chi^2 P = 0.28$ ; $\beta$ 21%	$\tau^2$ 0.00; $\chi^2$ P = 0.43; l <sup>2</sup> 0%	$\tau^2$ 0.01; $\chi^2$ P =0.23; $l^2$ 30%	
Stillbirths	RR 0.85; 95% CI: 0.74, 0.96	RR 0.72; 95% CI: 0.61, 0.84	RR 0.78; 95% CI: 0.70, 0.87	P = 0.28
	10 studies, 171,703	3 studies, $n = 4,980$	2 studies, n =29,927	
	$\tau^2$ 0.03; $\chi^2$ P = 0.0002; I <sup>2</sup> 72%	$\tau^2$ 0.00; $\chi^2$ P = 0.067; l <sup>2</sup> 0%	$\tau^2$ 0.03; $\chi^2$ P = 0.0001; l <sup>2</sup> 0%	
Perinatal mortality	RR 0.91; 95% CI: 0.84, 0.98	RR 0.75; 95% CI: 0.64, 0.89	RR 0.81; 95% CI: 0.64, 1.01	P=0.11
	9 studies, n <i>=</i> 149,079	5 studies, n =93,665	3 studies, $n = 32,184$	
	$\tau^2$ 0.01; $\chi^2$ P = 0.05; l <sup>2</sup> 48%	$t^2$ 0.03; $\chi^2$ P = 0.003; I <sup>2</sup> 72%	$\tau^2 0.03; \ \chi^2 \ P = 0.008; \ J^2 \ 75\%$	

(RR 0.70; 95% CI: 0.60–0.82; 4 studies, n = 61,176) (Table 3).

## Morbidity outcomes

From RCTs, significant results were observed in reducing any perceived illnesses in newborns (RR 0.61; 95% CI: 0.43–0.85; 2 studies, n = 12,019), however, no improvements were observed for maternal illnesses (RR 0.87; 95% CI: 0.65–1.15; 3 studies, n = 26,005) (Table 1). Results from non-RCTs were not significant for neonatal illnesses (RR 1.12; 95% CI: 0.90–1.39; 1 study, n = 459) (Table 2).

### Other care seeking outcomes

The review identified a number of RCTs which, when pooled, displayed a positive impact on care practices; these include antenatal care (RR 1.26; 95% CI: 1.16–1.37; 13 studies, n = 14,1006), receiving tetanus toxoid immunization (RR 1.07; 95% CI: 1.04–1.11; 8 studies, n = 83,243), and iron/folate supplementation (RR 1.49; 95% CI: 1.06–2.11; 6 studies, n = 81,706) (Table 1). Improved rates of institutional births (RR 1.15; 95% CI: 1.05–1.26; 16 studies, n = 116,848) and initiating breastfeeding within an hour of birth (RR 1.77; 95% CI: 1.43–2.19; 14 studies, n = 100,272) were also seen. However, no improvements were seen for SBA (RR 1.15; 95% CI: 0.99–1.34; 7 studies, n = 53,583).

For non-RCTS, similar significant improvements were observed on uptake of antenatal care (RR 1.05; 95% CI: 1.04–1.06; 3 studies, n = 31,305), iron/folate supplementation (RR 24.53; 95% CI: 13.20–45.59; 1 study, n = 756), institutional births (RR 1.89; 95% CI: 1.48–2.41; 2 studies, n = 2,291), and initiation of breastfeeding within an hour of birth (RR 6.54; 95% CI: 5.88–7.27; 1 study, n = 13,826). However, no improvements were observed for women birthing with a SBA (RR 1.03; 95% CI: 0.97–1.10; 1 study, n = 13,826) (Table 2).

For before-after studies, significant impact was observed for uptake of any antenatal care (RR 1.27; 95% CI: 1.24–1.30; 3 studies, n = 10137), tetanus toxoid immunization (RR 1.14; 95% CI: 1.10–1.17; 1 study, n = 3,480), and iron/folate supplementation (RR 1.29; 95% CI: 1.25–1.33; 1 study, n = 3,480) after an intervention was delivered but not for institutional births or early initiation of breastfeeding (Table 3).

## Discussion

Adequately addressing women's and children's health care needs would resolve a considerable proportion of global health problems. Improving health care seeking for the health of mothers and newborns can prevent many avoidable deaths. Although there was a paucity of included studies reporting health care seeking as an outcome, the systematic review found promising results of the several interventions for improving health care seeking for maternal and newborn illnesses. Although the impact was not

Table 4. (Continued)

significant for health care seeking for maternal illnesses, care seeking for neonatal illnesses improved by 40% overall. The impact was enhanced when the intervention was provided by CHWs though home visiting (45% increase) or when combined with community mobilization (62%), however the later evidence came from a single study with a positive impact. Impact was even larger when promotion of birth preparedness was combined with interventions where CHW recognized illnesses and provided referrals (65% increase). While interpreting the results, it is important to consider that studies were not similar across the subgroups for health care seeking for maternal illnesses and neonatal illnesses.

The included studies did not find any impact for any of these interventions on improving maternal mortality. Probably these studies were not powered to detect small but important differences. Significant improvements were observed for neonatal mortality (21% reduction) including early (30%) and late neonatal mortality (23%), stillbirths (18%), and perinatal mortality (18%). A similar direction of effect, although not significant, was found from non-RCTs and before/after studies. Although impact on mortality was more convincing when interventions were given in the form of community mobilization in combination with home visiting, the degree of heterogeneity was high. Mortality substantially improved when birth preparedness was combined with recognition of illnesses and provision of referrals; and was even more effective when interventions involved collection of funds for emergency transportation. However, the number of studies with increasing intensity of intervention decreased and there were too few studies in the highest level of intensity to make robust claims.

The review found positive impacts for these interventions from RCTs on improving antenatal care (27%), uptake of tetanus toxoid immunization (8%), iron/folate supplementation (49%), institutional births (16%), and initiation of breastfeeding (85%). Similar direction of effects was observed from other less rigorous study designs.

The subgroup analyses suggest that the impacts on health care seeking, mortality, and morbidity were greater when interventions included recognition of illnesses and provision of referrals. However, the qualitative findings from these trials were scarce and little or no information was provided to relate these findings with the contextual factors of delays in those scenarios. The literature suggests health service demand is not determined by recognition of problems and perceived seriousness alone; there are underlying beliefs which play a vital role in determining health care utilization patterns (46–48). Ineffective or inequitable health decision making at the household level is a major obstacles in accessing health care (49, 50). Timely recognition of danger signs, autonomy of decision making, availability of finances, accessibility of the health facility, and perceived quality of care are necessary considerations when making the decision to seek formal care.

Even though modest improvement in maternal and neonatal health outcomes has been achieved in the last decade, these can be further improved. While the use of advocacy groups and mobilization campaigns can help to optimize the implementation of these strategies; health system investment training the community and facility health staff and equipping them with essential supplies can help them care for a high risk pregnancy, as well as respond to any emergency that may arise. A specific implementation strategy could be the provision of birthing kits to the Traditional Birth Attendant (TBA)s which will ensure access for those residing in remote areas. This is likely to reduce mortality arising from delay in the provision of emergency medical aid during childbirth. In addition, indirect health care costs such as transportation and certain minor charges at the facility should be minimized. Full implementation of these changes will go a long way to improve not only maternal and neonatal health-seeking behavior, but also their health outcomes.

## Conclusions

This systematic review identified that strategies such as mobilization and home visitation can improve health care seeking for neonatal illnesses and can reduce perinatal mortality. Further analyses based on strategies which combined birth preparedness counseling with recognition of illnesses and provision of referrals by CHWs showed an improvement in both maternal and neonatal health care seeking. Similarly, strategies which used mobilization with home visitation showed an improvement in both maternal and newborn health care seeking; however the evidence was only derived from a single study. These interventions had a significant impact on reducing stillbirths, perinatal deaths, and neonatal mortality. Most of the included studies were conducted in Asia, with very a limited number of studies from other LMIC countries such as Africa. Thus, there is a clear need for additional high quality research from other LMIC regions. There is also a need to identify the cost-effectiveness of identified strategies to provide interventions in affordable ways to hard-to-reach communities to prevent illnesses and promote health.

## Authors' contributions

ZSL conceptualized the review in consultation with the co-reviewers (PM, CC, ZAB) and wrote the first draft of the paper with substantial inputs from PM, CC, and ZAB. ZSL and PM contributed to the scientific literature search, screening, collection, and analysis of data for all the included interventions with close inputs from CC and ZAB. All authors saw successive drafts of the paper and provided input. ZSL, PM, CC, and ZAB finalized the paper and are the overall guarantor.

## Conflict of interest and funding

ZAB was part of the following trials; however, he played no role in the quality assessment of these trials:

Bhutta ZA, Soofi S, Cousens S, Mohammad S, Memon ZA, Ali I, Feroze A, Raza F, Khan A, Wall S, et al.: Improvement of perinatal and newborn care in rural Pakistan through community-based strategies: a cluster-randomised effectiveness trial. Lancet 2011, 377(9763): 403–412.

Bull World Health Organ. 2008 Jun;86(6):452-9. Implementing community-based perinatal care: results from a pilot study in rural Pakistan. Bhutta ZA1, Memon ZA, Soofi S, Salat MS, Cousens S, Martines J.

This review was part of the first author's doctoral thesis which was funded as part of International Postgraduate Research Scholarship by University of Adelaide, Australia. The funders had no role in the study design, study conduct, data analysis, data interpretation, or writing of the report. All authors take responsibility for the integrity and the accuracy of the data. The corresponding author had final responsibility to submit the report for publication.

## Paper context

Reducing maternal and newborn mortality will require rigorous efforts to scale up evidence-based interventions, especially community-based preventive, promotive and therapeutic strategies, as well as availability of commodities and health workers in primary care. A lack of appropriate care seeking for ill mothers and neonates is thought to contribute to high mortality rates; therefore, a major challenge is the appropriate mix of strategies for demand creation as well as provision of services. Prior published reviews have systematically assessed the prevalence of care seeking in neonates; however the prevalence of care seeking among mothers has not been systematically assessed. Also there are no reviews which have assessed the strategies or interventions to increase care seeking for maternal and neonatal health. There is a need to systematically review the literature to determine the interventions that can improve the care seeking pattern among mothers and their newborns at primary care setting in developing countries.

## References

- World Bank (2014). Levels and trends in child mortality. Estimates developed by the UN inter-agency group for child mortality estimation (IGME) – report 2014. Washington, DC: World Bank Group.
- Alkema, Leontine; Chou, Doris; Gemmill, Alison; Hogan, Daniel; Mathers, Colin; Mills, Samuel; Moller, Ann-Beth; Say, Lale; Suzuki, Emi. (2014). Trends in Maternal Mortality: 1990 to 2013 - estimates by WHO, UNICEF, UNFPA, the World Bank, and the United Nations population division. Washington DC: World Bank Group.

- Black RE, Cousens S, Johnson HL, Lawn JE, Rudan I, Bassani DG, et al. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet 2010; 375: 1969–87.
- 4. UNICEF (2008). The state of the world's children 2008. New York: UNICEF.
- Darmstadt GL, Lee ACC, Cousens S, Sibley L, Bhutta ZA, Donnay F, et al. 60 million non-facility births: who can deliver in community settings to reduce intrapartum-related deaths? Int J Gynaecol Obstet 2009; 107: S89–112.
- Sines E, Tinker A, Ruben J. The maternal-newborn-child health continuum of care: a collective effort to save lives. Washington, DC: Save the Children and Population Reference Bureau; 2006.
- Bayer A. Executive summary: maternal mortality and morbidity. Population Resource Center; 2001. Available from: http:// www.prcdc.org/files/Maternal\_Mortality.pdf [Cited 10 Sep 2015].
- Lassi ZS, Bhutta ZA. Community-based intervention packages for reducing maternal and neonatal morbidity and mortality and improving neonatal outcomes. Cochrane Database Syst Rev 2015; 3: CD007754.
- Blencowe H, Cousens S, Kamb M, Berman S, Lawn JE. Lives saved tool supplement detection and treatment of syphilis in pregnancy to reduce syphilis related stillbirths and neonatal mortality. BMC Public Health 2011; 11(Suppl 3): S9.
- Blencowe H, Lawn J, Vandelaer J, Roper M, Cousens S. Tetanus toxoid immunization to reduce mortality from neonatal tetanus. Int J Epidemiol 2010; 39(Suppl 1): 102–9.
- Conde-Agudelo A, Rosas-Bermúdez A, Kafury-Goeta AC. Effects of birth spacing on maternal health: a systematic review. Am J Obstet Gynecol 2007; 196: 297–308.
- Demicheli V, Barale A, Rivetti A. Vaccines for women to prevent neonatal tetanus. Cochrane Database Syst Rev 2005; 4: CD002959.
- De-Regil LM, Fernández-Gaxiola AC, Dowswell T, Pena-Rosas JP. Effects and safety of periconceptional folate supplementation for preventing birth defects (Review). Cochrane Database Syst Rev 2010; 10: CD007950.
- Dowswell T, Carroli G, Duley L, Gates S, Gülmezoglu AM, Khan-Neelofur D, et al. Alternative versus standard packages of antenatal care for low-risk pregnancy. Cochrane Database Syst Rev 2010; 10: CD000934.
- Gamble C, Ekwaru JP, ter Kuile FO. Insecticide-treated nets for preventing malaria in pregnancy. Cochrane Database Syst Rev 2006; 2: CD003755.
- Garner P, Gulmezoglu AM. Drugs for preventing malaria in pregnant women. Cochrane Database Syst Rev 2006; 4: CD000169.
- Hofmeyr GJ, Lawrie TA, Atallah AN, Duley L. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev 2010; 8: CD001059.
- Lumley J, Chamberlain C, Dowswell T, Oliver S, Oakley L, Watson L. Interventions for promoting smoking cessation during pregnancy. Cochrane Database Syst Rev 2009; 3: CD001055.
- Pena-Rosas JP, Viteri FE. Effects and safety of preventive oral iron or iron + folic acid supplementation for women during pregnancy (Review). Cochrane Database Syst Rev 2009; 4: CD005462.
- Siegfried N, van der Merwe L, Brocklehurst P, Sint TT. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev 2011; 7: CD003510.
- Sturt AS, Dokubo EK, Sint TT. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women. Cochrane Database Syst Rev 2010; 3: CD008440.

- 22. Duley L, Henderson-Smart DJ, Meher S. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst Rev 2006; 3: CD001449.
- 23. Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2007; 2: CD004659.
- 24. Gulmezoglu AM, Crowther CA, Middleton P. Induction of labour for improving birth outcomes for women at or beyond term. Cochrane Database Syst Rev 2006; 4: CD004945.
- 25. Hofmeyr GJ, Gyte G. Interventions to help external cephalic version for breech presentation at term. Cochrane Database Syst Rev 2004; 1: CD000184.
- Jabeen M, Yakoob MY, Imdad A, Bhutta ZA. Impact of interventions to prevent and manage preeclampsia and eclampsia on stillbirths. BMC Public Health 2011; 11(Suppl 3): S6.
- Mousa HA, Alfirevic Z. Treatment for primary postpartum haemorrhage. Cochrane Database Syst Rev 2007; 1: CD003249.
- Lopez LM, Hiller JE, Grimes DA. Education for contraceptive use by women after childbirth. Cochrane Database Syst Rev 2010; 1: CD001863.
- Anita Z, Hammad G, Sana S, Simon C, Robert B, Zulfiqar B, et al. Effect of case management on neonatal mortality due to sepsis and pneumonia. BMC Public Health 2011; 11(Suppl 3): S13.
- 30. Bhutta ZA, Zaidi AKM, Thaver D, Humayun Q, Ali S, Darmstadt GL. Management of newborn infections in primary care settings: a review of the evidence and implications for policy? Pediatr Infect Dis J 2009; 28: S22.
- Dyson L, McCormick F, Renfrew MJ. Interventions for promoting the initiation of breastfeeding. Cochrane Database Syst Rev 2005; 2: CD001688.
- 32. Lassi ZS, Haider BA, Bhutta ZA. Community-based intervention packages for reducing maternal and neonatal morbidity and mortality and improving neonatal outcomes. Cochrane Database Syst Rev 2010; 11: CD007754.
- 33. Lewin S, Munabi-Babigumira S, Glenton C, Daniels K, Bosch-Capblanch X, Van Wyk BE, et al. Lay health workers in primary and community health care for maternal and child health and the management of infectious diseases. Cochrane Database Syst Rev 2010; 3: CD004015.
- 34. Sazawal S, Black RE. Effect of pneumonia case management on mortality in neonates, infants, and preschool children: a metaanalysis of community-based trials. Lancet Infect Dis 2003; 3: 547–56.
- Zupan J, Garner P, Omari AA. Topical umbilical cord care at birth. Cochrane Database Syst Rev 2004; 3: CD001057.
- Conde-Agudelo A, Belizan JM, Diaz-Rossello J. Kangaroo mother care to reduce morbidity and mortality in low birthweight infants. Cochrane Database Syst Rev 2011; 3: CD002771.

- Gogia S, Sachdev HS. Home visits by community health workers to prevent neonatal deaths in developing countries: a systematic review. Bull World Health Organ 2010; 88: 658–66.
- Lawn JE, Mwansa-Kambafwile J, Horta BL, Barros FC, Cousens S. 'Kangaroo mother care' to prevent neonatal deaths due to preterm birth complications. Int J Epidemiol 2010; 39(Suppl 1): 144–54.
- 39. Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included studies. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1. 0 [updated March 2011]. Cochrane Handbook for Systematic Reviews of Interventions Version. The Cochrane Collaboration 2011, Vol 5.
- Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. London: BMJ; 2001.
- Ottawa Hospital Research Institute (2013). EPOC resources. Suggested risk of bias criteria for EPOC reviews. Ottawa: OHRI.
- The Nordic Cochrane Centre TCC (2012). Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration.
- 43. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0; 2011 [updated March 2011]. The Cochrane Collaboration. Available from: http:// www.cochrane-handbook.org [Cited 10 Sep 2015].
- 44. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336: 924–6.
- Egger M, Smith GD, Schneider M, Minder C. Bias in metaanalysis detected by a simple, graphical test. BMJ 1997; 315: 629–34.
- Bhatia JC, Cleland J. Self-reported symptoms of gynecological morbidity and their treatment in south India. Stud Fam Plann 1994; 26: 203–16.
- Stewart MK, Stanton CK, Festin M, Jacobson N. Issues in measuring maternal morbidity: lessons from the Philippines Safe Motherhood Survey Project. Stud Fam Plann 1996; 27(1): 29–35.
- Fikree FF, Ali T, Durocher JM, Rahbar MH. Health service utilization for perceived postpartum morbidity among poor women living in Karachi. Soc Sci Med 2004; 59: 681–94.
- Essendi H, Mills S, Fotso JC. Barriers to formal emergency obstetric care services' utilization. J Urban Health 2010; 88(Suppl 2): S356–69.
- Pritham UA, Sammons LN. Korean women's attitudes toward pregnancy and prenatal care. Health Care Women Int 1993; 14: 145–53.